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ABSTRACT 
Recent trends in clinical neuroscience have moved toward identifying neurobiological 
predictors of antidepressant treatment effects in order to improve overall treatment efficacy in 
Major Depression, a pervasive and debilitating disorder in which complete remission occurs for 
only one-third of treatment-seeking patients. However, predictors of placebo effects have largely 
been overlooked. This is not a small concern: substantial placebo response rates have been 
documented within antidepressant clinical trials. Hence, neuroimaging predictors of placebo 
responses may elucidate the neural pathways responsible for depression recovery. Moreover, 
these predictors may identify patients with a greater susceptibility to placebo effects; in turn, 
informing patient stratification in antidepressant clinical trials to better distinguish between drug-
specific and placebo effects or augment prescribed treatments for patients in clinical settings.  
This dissertation takes a network-based resting-state functional connectivity (rsFC) 
approach to investigate predictors of placebo and antidepressant responses with particular focus 
on the default-mode, salience, and executive networks. This approach allows for consistency 
with the inherent network organization of the brain and the network-based characterization of 
depression. Through this investigation, enhanced rsFC of the rostral anterior cingulate (rACC) 
within the salience network has emerged as a strong predictor of responses to placebo with 
antidepressant expectations. Furthermore, heightened rACC rsFC within the salience network 
manifests as a neurobiological pattern differentiating healthy subjects from depressed patients. 
Finally, in light of evidence that genetic variability within placebo-related pathways modulate 
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placebo treatment outcomes in depression as well as analgesia, where neural and molecular bases 
of placebo have been extensively mapped, the final chapter of this dissertation observed an effect 
of genetic polymorphisms within the prepronociceptin gene, an endogenous opioid precursor 
neuropeptide associated with nociception and depression, on analgesic placebo-induced µ-opioid 
activation within the rACC and other well-established, placebo-related regions. This effect 
further corresponded with placebo-associated stress responses and anxiety. 
These findings enlighten our understanding of the neurobiology behind depression 
recovery through placebo effects and illustrate the importance of the rACC within antidepressant 
responses and healthy functioning. Finally, they contribute to a growing database of potential 
clinical neuroimaging and genetic markers of placebo responses which may substantially benefit 
therapeutic care in depression. 
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Chapter One 
Introduction 
 
A major goal in translational research is to improve treatment outcome and treatment 
efficacy for individual patients. This is particularly relevant for patients with Major Depressive 
Disorder (MDD), a pervasive and debilitating disorder which afflicts nearly one-fifth of the 
population at least once throughout a lifetime (1). The disorder predominately manifests with 
episodes of persistent negative mood (feeling down, sad, or hopeless) often concurrent with 
anhedonia (lack of feeling, or motivation for, pleasure), although the latter symptom may exist 
independently from a negative mood state and still be labeled as a depressive episode. Additional 
emotional, psychological and somatic symptoms also often occur. While the neurobiological 
underpinnings of such alterations from healthy functioning are still largely unknown, MDD is 
considered a network-based disorder (2), which targets specific brain regions (3, 4) and involves 
major neurotransmitter systems (5, 6), resulting in profound cognitive and affective dysfunction 
(7, 8). 
Currently, no definitive factor has been identified to cause or induce MDD within a 
patient. Instead, a combination and interplay of genetic and environmental risk-factors appear to 
contribute to disease manifestation: specifically, genetic heritability (9), personality traits such as 
neuroticism (10), or traumatic experiences or circumstances (11). The complex nature of the 
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disease is further complicated by the lack of efficacy of standard first-line treatments for MDD: 
complete remission after antidepressant medication or psychotherapy occurs only in a third of all 
patients seeking treatment (12). In general, the response rate – defined as a clinically meaningful 
reduction in depressive symptoms from baseline (~50%) – to either modality for standard 
antidepressant treatment is around 60%. Still, response to treatment, compared to absolute 
remission from symptoms, is associated with continued symptoms of impairment, and greater 
risk for relapse, episode recurrence, and suicide (13). Unfortunately, nearly a fifth of depressed 
patients may not demonstrate substantial, if any, improvement even after multiple, often 
intensive treatments (14).  
Translational neuroscience research has the potential to improve treatment outcome in 
MDD by investigating the neural basis of antidepressant treatment effects within patients who 
recover from depression. This recovery may stem from particular treatments such as 
antidepressant medication or psychotherapy, or it may result from non-specific treatment effects, 
such as the placebo effect, which derives from active neurobiological processes induced by 
expectations and therapeutic environmental cues (15). Overall, this research may benefit 
treatment efficacy for patients with MDD by elucidating the neurobiology involved in depression 
recovery and possibly specifying neurobiological targets for future drugs or other interventions. 
Moreover, this may also inform neurobiological predictors of treatment response to currently 
available treatments. Ultimately, using baseline markers to select optimal treatments for a given 
patient may amend treatment outcomes comprehensively: primarily, by reducing the duration 
until the onset of a treatment response. This response is often patient-specific, yet clinical 
antidepressant protocols are based on average outcomes from large-scale clinical datasets (16);  
hence, current practice often leads to experimentation with multiple drug or intervention types 
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until a patient finally achieves a clinically meaningful response. Furthermore, this contributes to 
a decreased likelihood of remission after each treatment attempt (14% and 13% after third and 
fourth attempts versus 37% and 31% after first and second phase of treatment, respectively) (12). 
Therefore, a better grasp of the biological markers associated with treatment response may 
enable an earlier achievement of response. Altogether, improvement in antidepressant treatment 
efficacy may result in substantially diminished costs of treating depression: The financial burden 
of MDD-induced disability and related treatment totaled $210 billion in the United States alone 
in 2010 (17). Nearly half of this was attributed to treatment for MDD and comorbid disorders 
like anxiety, largely due to prolonged antidepressant treatment duration and unsuccessful 
antidepressant drug clinical trials (18). 
We propose that investigating the neurobiology of treatment effects in depression in order 
to uncover the associated mechanisms responsible for depression recovery will have a substantial 
impact on treatment efficacy for MDD. Insights gained will have the potential to inform future 
treatment targets within patients, either by predicting the ideal treatment modality for individual 
patients or developing novel methods with antidepressant effects. This personalized medicine 
approach is particularly important for diseases such as MDD, for which multiple 
etiophathological mechanisms are believed to produce a similar clinical phenotype (19). For 
instance, although effective, targeting specific regions known to function abnormally within the 
disease, such as the dorsolateral prefrontal cortex (dlPFC) (20, 21), as in transcranial magnetic 
stimulation (TMS) (22), or the subgenual anterior cingulate  (sgACC) (23), as in deep brain 
stimulation (DBS) (24), does not result in absolute remission across all subjects. At the same 
time, diffuse treatments such as serotonin reuptake inhibitors (SSRIs) or electroconvulsive 
therapy (ECT) also do not provide consistent, reliable treatment effects across patients (14). 
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Therefore, mapping the neurobiology associated with general MDD recovery or with a particular 
antidepressant modality may identify neural mechanisms necessitating a successful treatment 
response. Concurrently, this may enhance our ability to stratify patients according to their 
biologically optimal treatments. Here, we describe important findings from studies investigating 
neurobiological antidepressant treatment effects and how they have contributed to our 
understanding of the neural basis of MDD. Moreover, these treatment effects also stem from 
non-specific effects of treatment administration, notably the placebo effect, which has 
consistently been implicated in antidepressant treatment and its pharmacological development 
(18, 25, 26). Thus, we describe the significance of the placebo response in treating patients with 
depression; specifically, the existing knowledge of the neural mechanisms associated with this 
clinically meaningful treatment effect.  
Neurobiology of Treatment Response and Disease 
Examining the neurobiology behind the antidepressant response has elucidated the major 
theory behind the disorder: that it materializes from a dysregulation of cortical and limbic 
networks (27). In a landmark study using positron emission tomography (PET) and measures of 
glucose metabolism in a group of depressed men receiving fluoxetine, a standard SSRI 
antidepressant, Mayberg et al. (28) demonstrated that after six weeks of administered treatment, 
response was associated with decreases in limbic-paralimbic and striatal regions – sgACC, 
anterior insula, thalamus, hippocampus, striatum – and increases in brainstem and cortical 
regions – prefrontal, anterior and posterior cingulate cortex, and the inferior parietal cortex. This 
pattern differentiated responders from non-responders. While both groups demonstrated identical 
glucose metabolism changes after one week of antidepressant treatment – brainstem and 
hippocampal increases; striatal and posterior cingulate cortex decreases – ultimately, non-
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responders demonstrated a continuation of this pattern and an absence of sgACC metabolism 
decreases and concurrent prefrontal metabolism increases as observed within the responders 
(28). This initial brainstem and hippocampal change followed by eventual metabolic cortical 
changes is in line with antidepressant medication effects outlined in rodent models (29). 
Furthermore, this general finding of treatment-induced enhancement of cortical activity and 
diminished limbic activity is consistent across medications (30, 31) and has relevance across 
treatment modalities: A similar pattern of decreased sgACC metabolism and increased 
metabolism within frontal, executive regions like the dlPFC was also observed within depressed 
patients who were responsive to DBS of the sgACC (24). On the other hand, implementation of 
psychotherapy demonstrates an overlap, but also a unique set of changes in brain function 
compared with medication. Specifically, cognitive behavioral therapy (CBT) is associated with 
metabolic increases within the hippocampus and dorsal cingulate, yet with reductions within 
prefrontal dorsal, ventral, and medial regions (32). In another study, both CBT and medication 
induced a reduction in the dorsomedial and lateral orbital prefrontal cortex, however, decreases 
in glucose metabolism within a posterior portion of the sgACC was specific to venlafaxine, a 
serotonin norepinephrine reuptake inhibitor (33).  
These findings have support within the literature of MDD neurobiology. Generally, the 
most consistent finding is decreased frontal lobe function, localized mostly within the 
dorsolateral, ventrolateral, and orbital prefrontal cortex (34). Opposite patterns have also been 
observed, which may speak to a separate disease etiology or possibly, compensatory mechanisms 
resulting from MDD-related deficits in functioning (27). Concurrently, brain regions which drive 
mood and interoceptive states such as the sgACC, anterior insula, and hippocampus, as well as 
regions associated with the monitoring of salient, mood-related stimuli such as the thalamus and 
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amygdala seem to show greater reactivity in MDD (23, 35-38). Particularly, the sgACC is an 
important region – consistently hyperactive in depression (23, 24) which subsequently, best 
characterizes treatment-resistant depression (33). Furthermore, normalization of its excessive 
activity is associated with response to first-line treatments like medication or from more 
intensive treatments such as DBS (24, 33, 39). Broadly, the sgACC is linked with regulating 
negative emotional states: its activity is associated with active induction of negative mood via 
retrieval of sad, autobiographical memories, or via pharmacology (40, 41), or via passive 
exposure to sad or unpleasant stimuli (42).  
Midline cortical brain regions are critical for mediating the relationship between 
diminished frontal lobe functioning and enhanced limbic activity. Chiefly, these regions are 
responsible for incorporating self-referential value into the processing of incoming stimuli, 
regulating limbic-driven emotional and mood states, and relaying this information to executive 
cortical regions, as well as the reciprocal communication pathway. Included regions are the 
medial prefrontal cortex (mPFC), the dorsal (dACC) and rostral ACC (rACC). The rACC is a 
region of consequence in major depression, as successful, sustained antidepressant response is 
associated with hyper-metabolism in the region across treatments (31, 32); while diminished 
metabolism associates with non-response (43); and pretreatment rACC activity is a common 
indicator of eventual treatment response (44). It also mediates the interaction between the mPFC 
and the more primitive, limbic-driven amygdala during self-referential processing of negative 
stimuli; this latter pattern has been shown to be excessive in patients with depression relative to 
healthy subjects (45) and a classic characteristic of depressive neurobiology [reviewed (46)].  
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Placebo Effects in Major Depression 
Remarkably, high and growing rates of placebo responses occur within MDD (47), 
substantially hindering development of novel therapeutics and predictors of treatment response. 
This failure to differentiate placebo from antidepressant responses has caused large 
pharmaceutical companies to reduce or discontinue research focused on antidepressant treatment 
(48). In light of this, several strategies have been implemented to improve sensitivity of 
treatment-specific effects in clinical trials, primarily by reducing the number of placebo 
responders that enter a clinical trial and thus, the overall placebo response rate: including the use 
of placebo lead-in phases or sequential parallel comparison designs (49). One major limitation of 
these approaches is that results are ultimately obtained from placebo non-responders, which may 
not be generalizable to all patients with depression. Moreover, placebo responders may require 
lower doses of antidepressant treatment or no active treatment, which would contribute to a 
comprehensive reduction of the overall cost (50) and risk (51) of using antidepressants. 
Furthermore, ratings scales used to measure both placebo and antidepressant effects are 
imprecise and highly influenced by other factors, such as regression to the mean or natural 
fluctuation of symptoms, making the evaluation of treatment effects more nebulous. As a 
consequence, placebo effects continue to be a great barrier to the development of novel and 
successful therapeutics.  
In contrast, since the neurobiology of placebo analgesia was discovered 35 years ago (52), 
neuroscientists have made substantial headway in identifying the cognitive, neural and molecular 
bases of placebo effects (53-57) in the field of pain; inadvertently, describing important 
pathways involved in homeostatic, stress, and reward responses. By contrast, only two existing 
studies have investigated the neural basis of placebo effects as they relate to depression (58, 59). 
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Still, the findings have proven to be consequential: Mayberg’s initial work describing glucose 
metabolism changes in response to antidepressant treatment also demonstrated a localized 
overlap in glucose metabolism changes within placebo and antidepressant responders. Namely, 
increases in cortical areas and decreases in limbic areas following six weeks of fluoxetine 
treatment. Increases in brainstem metabolism and decreases in the anterior insula, striatum and 
hippocampus were specific to drug responders (59). However, after one week of treatment, 
eventual drug and placebo responders demonstrated a unique, shared pattern of glucose 
metabolism increases within the ventral striatum and orbitofrontal cortex, regions implicated in 
selection and expectations of rewarding stimuli. This neural pattern is theorized to underlie 
beneficial anticipatory, non-specific effects of treatment which lend to the placebo and overall 
antidepressant response (60). 
The convergence of regional changes in brain function across responders to placebo and 
antidepressant treatment is imperative. As previously mentioned, placebo effects are consistently 
apparent in antidepressant randomized clinical trials (61), however, they also emerge across 
alternative treatments such as CBT (62, 63) or sham ECT (64). More specifically, within 
antidepressant clinical trials, placebo response rates are variable and range from 30-45% 
compared to around 50% for pharmacological drugs. In the last 30 years, the rate of placebo 
responses has been steadily increasing, nearly 10% each decade (47, 65). While these high, 
variable rates of placebo response have hindered rates of successful drug clinical trials –nearly 
half of all trials of approved antidepressants fail to show statistically significant separation 
between drug and placebo arms (66) – they also point to the therapeutic currency of non-specific 
effects of treatment. Incredibly, the placebo response arises from the psychosocial context in 
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which treatments are administered and manifests from a set of active neurobiological processes 
created from a set of expectations and conditioning within the therapeutic environment (15).  
This capacity to engage neurophysiological mechanisms as a result of cognitive and 
emotional factors from a particular treatment and its environmental context represents a domain 
with great promise to inform our understanding of the neurobiological processes involved in 
resiliency to illnesses, such as depression (67). Within these mechanisms, there is substantial 
inter-individual variability as reflected in the range of placebo response rates (47), antidepressant 
response rates (14), and the nature of each individual patient’s characteristic treatment response – 
for instance, psychotherapy is more beneficial for some patients than medication (68, 69). This 
variability is further supported by distinct patterns of brain metabolism after SSRI treatment 
versus psychotherapy (32, 59). However, a convergence in resiliency mechanisms does exist: 
effects of placebo and antidepressant medications share patterns of brain activity changes, as 
described above (59). It is likely that an interaction between drug and placebo mechanisms exists 
and contributes to the complete antidepressant response. However, further work is essential to 
disentangle treatment-specific from non-specific effects to better define the neural basis of 
resiliency to depression, which manifests in a reduction of depressive symptoms. Moreover, 
biological predictors of placebo responses and the nature of their modulation within a clinical 
response may also further inform our understanding of the neurobiological cognitive machinery 
responsible for ameliorating depressive symptoms as well as its variable nature between patients.  
Neurobiology of the Placebo Effect 
As briefly outlined above, substantial progress has been made in the field of placebo 
analgesia in defining the neural circuitry involved in placebo responses. Many of the findings 
from this research correspond with placebo-associated brain regions and neurotransmission in 
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Parkinson’s disease (56, 70). Circumspectly, the neural circuit described to form the basis of 
placebo responses includes the rACC, dorsolateral and orbitofrontal cortex, insula, nucleus 
accumbens (NAc), amygdala, thalamus and periaqueductal grey (PAG). Dopaminergic and 
opioid neurotransmission in these regions have been shown to modulate certain aspects of the 
placebo analgesic response including expectations (71), reward saliency of the placebo (55), and 
changes in experience of affective and pain intensity (72, 73).  
Over three decades ago, the µ-opioid neurotransmitter system, implicated in homeostatic 
(74), stress and reward mechanisms (75), was linked to the placebo response from an observation 
that placebo analgesic effects were blocked by naloxone, an antagonist with high affinity for µ-
opioid receptors (MORs) (52). Evidence for this connection was furthered in a pivotal study in 
which PET imaging of regional blood flow was compared between the analgesic effects from 
administration of a placebo with expectations of analgesia and a fast-acting opioid analgesic, 
remifentanil: a convergence of increased blood flow within the rACC and PAG was observed 
across placebo and opioid analgesic administration (57). Remarkably, the rACC, implicated in 
self-referential executive and affective cognition, projects directly to the PAG, a primary 
modulator of pain signaling (76). 
From our laboratory, more direct evidence of placebo-induced µ-opioid 
neurotransmission has been found utilizing PET and a selective μ-opioid radiotracer [11C] 
carfentanil in conjunction with a pain challenge and placebo administration with expectations of 
analgesic effects: Placebo administration was significantly associated with endogenous µ-opioid 
activation within the rACC, sgACC, anterior insula (aINS), and the NAc (73). This activation 
also corresponded with participants’ self-reported reductions of the physical and emotional 
elements of pain. In contrast, observed placebo-induced dlPFC opioid activation was negatively 
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related to the expectations of potential analgesic effects. This latter relationship was further 
developed with the finding that increased opioid activation within the region corresponded with 
higher expectations, but not with actual analgesic effects (71). Therefore, the region appears to 
be involved with the anticipatory component of a placebo response, which has been substantiated 
within a functional Magnetic Resonance Imaging (fMRI)-based placebo paradigm (72). A 
subsequent study utilizing the same, but more controlled, pain and placebo challenge 
demonstrated placebo-induced opioid activation within similar regions: rACC, sgACC, aINS, 
and the NAc. Additional activation was also observed within the orbitofrontal cortex, posterior 
INS, thalamus, amygdala, and PAG. More specifically, analgesic expectations prior and during 
administration of placebo associated with the NAc, PAG, and amygdala, while activity within 
the rACC and NAc corresponded to the experience of pain intensity. 
The cognitive aspect of placebo responses also informs our understanding of its 
associated neural pathways. Placebo responses have been hypothesized to materialize primarily 
from expectations of the treatment effect or, in contrast, from prior conditioned learning about 
the treatment’s effects. However, extant studies have found evidence to refute both theories 
[reviewed (15)]. Instead, recent work in our laboratory has demonstrated evidence for a Bayesian 
learning framework in which both types of processes are aptly incorporated. Here, placebo 
responses emerge as a consequence of therapeutic expectations from verbal and environmental 
cues and eventual outcomes, also partially influenced by conditioned learning. A pain and 
placebo challenge documented a lack of relationship between placebo response and expectations 
of analgesic effects. Instead, placebo responses were associated with a prediction error: 
individuals with the largest discrepancy between their expectations of analgesic effects and their 
actual perceived experience (perceived outcome>expectations) demonstrated the greatest placebo 
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responses. Prediction error was also associated with placebo-induced opioid activation in 
established placebo analgesic brain regions (ACC, insula, amygdala, thalamus) (71).  
Placebo Effect: Reward  
 Dopamine neurotransmission has also been implicated within placebo neurobiology (53, 
55, 56, 70). In analgesia, PET imaging with the selective dopamine D2/D3 radiotracer, [
11
C] 
raclopride has shown that placebo administration with expectations of analgesic effects is 
associated with dopamine activation within the mesolimbic dopamine terminal, specifically, the 
caudate, putamen and NAc. Moreover, placebo-induced NAc dopamine activation positively 
correlated with the magnitude of opioid activation in the same region, putamen, amygdala, 
anterior and posterior INS, and the rACC. This is consistent with the hypothesis that NAc 
dopamine activation initially detects the saliency and reward value of the placebo and triggers 
downstream opioidergic activation (53, 77). Furthermore, greater reward-related fMRI blood-
oxygen-level-dependent (BOLD) activity within the NAc has been found to significantly 
associate with increases in placebo-induced dopamine activation in the same region and placebo 
analgesic responses (55). 
  Of interest, deactivation of opioid and dopamine neurotransmission within participants 
who experienced a nocebo response or a worsening in their nociceptive experience after placebo 
administration has also been documented (53).  
Placebo Effect: Personality Prediction 
Investigation into placebo-related personality traits may be an accessible avenue to 
substantially improve clinical practice and clinical trials by identifying patients more susceptible 
to placebo effects; however, further work is necessary to incorporate these traits as their 
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predictive nature is influenced by other factors within a treatment context (78). Still, work in our 
laboratory observed that subjects with high levels of ego-resiliency, altruism and 
straightforwardness and low levels of anger and hostility showed greater placebo responses along 
with greater placebo-induced μ-opioid activation within well-documented placebo-related 
regions: ACC, orbital frontal cortex, INS, NAc, amygdala and PAG (79).  
Placebo Effect: Genetics and Prediction of Placebo Response 
Genetic markers are major candidate predictors of placebo responses, as recent work 
describes that the predisposition to respond to placebo may be, in part, a stable heritable trait. 
Mounting evidence has described genetic variation to modify placebo-associated pathways and 
in turn, placebo effects in depression, as well as in pain and other disorders [reviewed (80)]. 
Therefore, genetic screening may be a valuable tool in predicting placebo responses in patients 
with MDD and for further investigation of the neurobiology behind the placebo response. 
Evidence from studies analyzing placebo treatment across disorders has uncovered associations 
between placebo responses and genetic variation within important pathways involving 
dopaminergic, opioid, cannabinoid and serotonergic synthesis and signaling (54, 81-83). 
Specifically, work from our laboratory has provided evidence of genetic variation within the µ-
opioid receptor gene (OPRM1) to influence analgesic placebo-induced dopaminergic activation 
(82). Examination of genetic variation has also uncovered involvement of the endocannabinoid 
system in µ-opioid-mediated placebo analgesia. Participants homozygous for the FAAH  Pro129 
allele – a functional missense variant of the fatty acid amid hydrolase (FAAH) gene encoding the 
major endocannabinoid degrading enzyme, who exhibit lower levels of endocannabinoids due to 
increased FAAH activity, reported higher placebo analgesic responses and placebo-induced 
opioid activation within the prefrontal cortex, ACC, INS, hippocampus, NAc and thalamus (54). 
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Antagonism of the system has also been shown to block non-opioid mediated placebo responses 
(84).  
Interestingly, genetic markers implicated in dopaminergic and serotonergic pathways 
have been implicated in placebo responses. The variation within the gene for the monoamine 
oxidase A enzyme (MAO-A), involved in MDD through its essential role in metabolizing 
serotonin and dopamine, major players in MDD neuropathophysiology (85, 86), demonstrates an 
association with antidepressant placebo treatment: Individuals with low-activity of MAO-A, and 
therefore, higher dopaminergic and serotonergic tone, showed significantly higher antidepressant 
placebo responses than their genetic counterparts with highly active MAO-A (87). Across 
disorders, genetic variation within the gene encoding the major dopamine metabolizing enzyme, 
catechol-O-methyltransferase (COMT) also modulates placebo effects in patients with irritable 
bowel syndrome: those carrying the ‘met’ allele, who show reduced enzymatic activity and 
hence, increased prefrontal dopamine levels, were placebo responders, unlike their genetic 
counterparts who were unresponsive to placebo treatment (81). 
Placebo Neurobiology from Analgesia to Major Depression 
Regardless of the major potential contributions which may result from the examination of 
placebo neurobiology, this type of research in patients with MDD is currently limited (59).  
Moreover, our recent work has demonstrated the significance of placebo responses in 
antidepressant treatment: reductions in depressive symptoms in response to one-week of placebo 
administration with expectations of antidepressant effects were associated with greater placebo-
induced activation of µ-opioid neurotransmission in the sgACC, NAc, thalamus, and amygdala 
(88). Moreover, greater placebo-induced endogenous opioid release was associated with better 
response to subsequent administration of antidepressant medication. Not in the least, the 
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observed placebo-related opioid neurotransmission occurred in regions also involved in MDD 
disease pathology (46), and a network responsible for regulating stress and emotion (89, 90) and 
overlap with those involved in placebo analgesia neural circuitry (67). Overall, this supports a 
tight interplay between placebo and antidepressant treatment effects within a clinical response in 
patients with MDD.  
Altogether, the placebo response is a complicated neurobiological process which recruits 
multiple cognitive and emotional processes across brain regions and neurotransmitter systems. 
Given the intimate nature of the opioid and dopamine systems described in the neural basis of 
placebo analgesia, placebo mechanisms are associated with pathways related to homeostatic 
responses to stressful stimuli, and saliency and evaluation of rewarding stimuli. Similar 
mechanisms are also believed to underlie a substantial portion of MDD pathophysiology: 
abnormal homeostatic functioning after exposure to or interaction with a stressful or fearful 
stimuli, generally, with emphasized negative saliency (14), as well as abnormal reward 
processing are believed to contribute to symptoms of apathy and anhedonia (91). Therefore, 
investigating placebo neurobiology as it relates to depression may inform and eventually 
capitalize upon the neurological resiliency mechanisms which combat depression or the general 
mechanisms responsible for addressing any major stressors on the organism (77). Moreover, 
greater detail regarding MDD placebo neurobiology and its predictors, whether they are brain 
patterns obtained from clinical neuroimaging or genetic markers, can provide critical insight 
toward the improvement of clinical practice by identifying patients more susceptible to placebo 
effects and toward enhancing our understanding of the neurobiology behind recovery from 
depression.  
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Future Directions for Major Depression Treatment: Predictors of Treatment-Specific and Non-
Specific Effects 
Investigation of structural and functional predictors of treatment response in MDD is a 
nascent field with vast potential to improve antidepressant treatment outcomes. Functionally, and 
most consistently, the aINS and rACC are strong predictors of treatment response. While the 
insula demonstrates some conflicting findings (92-94), there is strong evidence the region may 
act as a treatment selector between those of varying levels of invasiveness (95). The rACC is an 
important predictor of treatment response [reviewed (96)]; increased pretreatment activity across 
imaging modalities – PET measuring regional blood flow and glucose metabolism, 
electroencephalography (EEG), single-photon emission tomography (SPECT), and resting and 
task-based fMRI – in this region is significantly associated with better response to many types of 
antidepressant treatments like medications, sleep deprivation, and repetitive TMS. Specifically, 
responders to antidepressant medication demonstrate enhanced metabolism within the rACC in 
relation to healthy controls. Moreover, this pattern differentiates responders from non-
responders, with the latter group exhibiting diminished metabolism within the rACC in 
comparison to healthy controls (44).  
Structural predictors of treatment response have also been identified. Reduced grey 
matter in the right hippocampus and the left dlPFC are both indicative of a poor response to 
antidepressant medication (97); whereas, data from nearly 200 patients with depression show 
that larger left hippocampal volume is predictive of a beneficial response to antidepressant 
medication (98). Thus, grey matter integrity within the hippocampus and dlPFC, two major 
regions involved within the pathology of MDD (99) is a potential biomarker of treatment 
response. Larger grey matter volume within the rACC and the insula has also been reported to 
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predict better treatment outcome with medication (100). Moreover, more substantive white 
matter integrity of the left cingulum bundle, or anterior cingulate-limbic white matter, is also 
significantly predictive of remission from antidepressant medication (101).  
On the other hand, one of the most consistent predictors of non-response to standard 
treatments is heightened metabolic activity of the sgACC: this is valid for antidepressant drugs as 
well as psychotherapy (102, 103). This is of interest, as DBS within this region produces 
significant recovery in patients with treatment refractory MDD (24). Moreover, increased 
efficacy of rTMS has been associated with the extent to which the selected area for magnet 
placement, within the dlPFC, anti-correlates with the sgACC (104). Identification of predictors 
of non-response to treatment can assist in streamlining patients to more invasive treatments 
immediately after seeking treatment. This is with the hope that years of non-response to more 
standard treatments would be averted.  
Alternative predictors may stem from personality traits or more stable, genetic variants. 
However, familial studies demonstrate that antidepressant treatment response is highly variable 
(105). Furthermore, genetic variants are known to interact with environmental factors or life 
events which predispose individuals to MDD and may influence responses to SSRIs (106, 107). 
While no consistent genetic marker exists in treatment response prediction, variations within the 
promoter region of MAO-A have been observed to significantly associate with antidepressant 
treatment response in females (108). In addition, genetic variations within the tryptophan 
hydroxylase 1 gene (TPH1), involved in serotonin synthesis (109), and brain-derived 
neurotrophic factor gene (BDNF), involved in behavioral antidepressant effects (110), have 
demonstrated a significant association with antidepressant treatment response [reviewed  (111)]. 
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Notably, the same functional BNDF 66Val/Met polymorphism exhibits an effect on dopamine 
activation in response to placebo administration with analgesic expectations (112).  
Predictors of Non-Specific Treatment Effects: The Placebo Effect 
Studies which have investigated predictors of antidepressant treatment response have 
implemented an open-label design which overlooks the contribution of the placebo effect within 
the antidepressant treatment response. This is of consequence since similar regions found to 
associate with the prediction of and involvement in the antidepressant treatment response – the 
rACC, insula, and dlPFC – have also been consistently described in the neurobiology of placebo 
analgesia. The rostral ACC demonstrates a pivotal, intricate role within the formation of placebo 
responses by recruiting and modulating subcortical anti-nociceptive regions, like the PAG, 
during placebo-induced analgesia (113). Moreover, in addition to fMRI BOLD activity,  PET-
based opioid and regional blood flow have all independently documented the region’s critical 
involvement in placebo analgesic effects (57, 72, 73). Further emphasizing its capability to 
moderate such a comprehensive mechanism, the rACC is involved in regulating self-referential 
emotional, cognitive, and reward processes (45, 114, 115). In connection to MDD, this key 
placebo region often demonstrates aberrant activity within depressed patients, in isolation or 
within the context of rewarding or negative stimuli (91, 116, 117); not in the least, is its 
consistent emergence from several meta-analyses as a neural predictor of antidepressant 
treatment response (96, 97). 
Moreover, the opioid system, intimately related to placebo analgesia, is an emerging 
target for antidepressant treatment (118). In parallel, the dopamine system has long been 
implicated in the pathophysiology and treatment of major depression. Major antidepressant 
medications influence dopamine neurotransmission and the system is believed to be a primary 
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driver of a subset of MDD etiologies (86). Abnormalities within the same reward circuitry 
implicated in placebo analgesia (55, 67) have also been described as a major facet of MDD 
neuropathophysiology [reviewed (119)]. Still, the neurobiology of placebo in depression has 
been largely discounted, despite the mounting convergence of evidence across neural pathways 
associated with placebo and MDD neurobiology. Overall, these findings illustrate the profound 
import placebo neurobiology may have in depression. The main objective of this dissertation is 
to investigate predictors of antidepressant treatment effects, primarily, predictors of placebo 
effects. Specifically, we are interested in clinical neuroimaging-based predictors because they 
provide insight into the neural basis of depression recovery as well as provide an objective, 
clinical marker, impermeable to patient or clinician biases or other confounds. Additionally, we 
are interested in clinical neuroimaging predictors under genetic influence to contribute to the 
growing ‘placebome’ [the group of genes, including their related pathways and molecules, 
hypothesized to affect an individual’s response to placebo treatment (80)] and further uncovering 
the neural correlates of placebo responses.  
Our primary focus on placebo responses is of relevance as current literature has largely 
ignored placebo effects inherent within overall antidepressant effects when examining predictors 
of treatment outcome. It is feasible that many predictors are capturing the placebo response or an 
interaction between the active treatment and the placebo. Differentiating treatment specific from 
non-specific effects may substantially inform future treatment targets and better define the neural 
basis of depression recovery. Moreover, identifying predictors of placebo response is critical to 
improve clinical practice and clinical trials for novel pharmacological agents: patients with 
greater likelihood of responding to placebo may benefit from lower dosages of medication, 
cognitive-based therapy, or enhanced patient-clinician interactions. They may also be ideal 
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candidates to investigate placebo and treatment-specific interactions. Alternatively, they may be 
separated from likely placebo non-responders to enable examination of drug effects in the 
absence of a placebo response, which would define drug effects in a specific subset of depressed 
patients.  
While we are focused on clinical neuroimaging and related genetic markers, 
accumulation of comprehensive evidence for various treatment response predictors (functional + 
structural neuroimaging + genetic variants + personality traits + treatment and disease history) 
will enable neuroscience and psychiatry to ultimately obtain a relative footprint of treatment 
response affinity and specificity within a patient with MDD. This is all in the quest to 
substantially improve treatment efficacy for each individual patient. 
Here, we employ a neurobiological perspective of network-based resting-state functional 
connectivity in order to investigate predictors of placebo effects in addition to overall 
antidepressant treatment effects. Although wide-spread and complex, MDD is generally 
described as a network-based disorder (2); therefore, our network-based approach to investigate 
neurobiological predictors of antidepressant treatment effects is fitting. Furthermore, recent work 
has demonstrated that the human brain is organized into wide-spread, cohesive, functionally 
connected networks (120-122). This finding has largely stemmed from research within a 
relatively recent field in neuroscience, resting-state functional connectivity (123), which 
measures the extent to which regions demonstrate a correlation between their fMRI BOLD 
signals in the absence of a task paradigm. Enhanced functional connectivity is thought to 
demonstrate more cohesive communication between regions or within a network. Importantly, 
examining brain function at rest may reduce variability across studies as well as obtain a better 
understanding of existing neural activity which contributes to the maintenance of MDD without 
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the presence of excessively salient stimuli (i.e. an fMRI task). Currently, resting-state functional 
connectivity is only beginning to emerge with conclusive MDD-related findings (23, 124, 125). 
However, as the methodology improves and becomes more standardized (126), functional 
connectivity may be an important tool in furthering our understanding of MDD neurobiology.  
Chapter Two 
 In light of this, in the second chapter of this dissertation, we implement network-based 
resting-state functional connectivity to investigate predictors of antidepressant treatment effects 
within a randomized one-week placebo trial and within a subsequent ten-week, open-label 
antidepressant trial. Specifically, three networks will be investigated: the default-mode, salience, 
and executive networks because all three are believed to play a major role within MDD (127, 
128). We will also investigate their relationship to depression severity. Finally, with the objective 
that these potential predictors may augment future clinical trials or treatment within a clinical 
setting, we applied machine learning algorithms to determine whether baseline, inherent 
functional connectivity may predict treatment effects at an individual subject level. Overall, we 
hypothesize that functional connectivity of the default-mode network will be positively 
associated with depression severity, based on prior literature (23, 129). Furthermore, regarding 
their implication in MDD and placebo analgesia, as described above, we hypothesize that 
functional connectivity of the rACC, dlPFC, and insula within their respective networks will 
predict response to one-week of placebo and ten-weeks of antidepressant administration.  
Chapter Three 
 In the third chapter of this dissertation, we continue with our network-based resting-state 
functional connectivity approach in order to investigate neurobiological differences between a 
group of depressed subjects and healthy controls. This is with the intention that 1) potential 
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predictors of treatment effects may indicate neurobiological patterns that differ in depression 
from a healthy state since successful antidepressant response associates with healthier (i.e. less 
depressed) states of functioning. 2) Examination of neurobiological patterns which differentiate 
depression from healthy functioning may expand and detail potential treatment targets and our 
general understanding of the disorder. Finally, we also employ an alternative resting-state 
functional connectivity analytical method to highlight the contributions and restrictions of 
currently, yet still novel, available methods. We hypothesize that any resultant treatment effect 
predictors will show reduced functional connectivity within the group of depressed patients. 
Additionally, we hypothesize that default-mode network and salience network functional 
connectivity will be greater in depressed subjects, based on prior theories (127) [connectivity of 
the default-mode network has shown conflicting findings (125), whereas the salience network 
has not yet been explored], while the opposite pattern is expected within the executive network 
due to documentation of network hypo-connectivity within the disorder (130).  
Chapter Four 
Finally, in keeping with the substantial progress in mapping neural mechanisms 
responsible for placebo analgesic effects, we sought to capitalize on this advancement and 
demonstrate the potential of neuroimaging-genetic markers to modulate placebo analgesic 
responses and thus, further define its neurobiology. To do so, we selected the prepronociceptin 
(PNOC) gene – a  neuropeptide precursor which has been associated with MDD (131), a member 
of the endogenous opioid family with expansive therapeutic potential (132), and extensively 
involved in nociception (133) – as a candidate genetic marker of placebo analgesic responses. To 
investigate this, we will examine the effect of PNOC polymorphisms on the activation of µ-
opioid neurotransmission in response to placebo administration with expectations of analgesia in 
23 
 
the context of a pain challenge. Through these genetic variations, we will also explore placebo-
associated stress responses and personality traits to further examine neurobiological correlates of 
the placebo effect.  
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Chapter Two 
Investigating Predictors of Treatment Response in Major Depression 
Major depressive disorder (MDD) has recently been conceptualized as a disorder with a 
network-based pathophysiology (2). Particularly, MDD manifests in cortico-limbic network 
dysregulation reflected by deficits in cognitive control and increased sensitivity of limbic 
networks (27, 130, 134, 135), which is thought to result in excessive and negatively-skewed 
focus on introspective processes, difficulty regulating emotions, and persistent difficulties in 
sustaining attention (7, 46). Regions involved in these networks have emerged as biological 
markers of response to antidepressant treatments (21, 58, 93, 95, 136, 137). Yet, the ability of 
these biomarkers to selectively distinguish drug-specific effects from other non-specific elements 
of the treatment response, such as the placebo effect, is still limited, with very few studies 
specifically addressing biomarkers of non-specific elements of antidepressant treatment response 
(59, 138). This is not a small concern, as placebo response rates in antidepressant clinical trials 
average 31-45% compared with response rates to antidepressants of ~50% and have increased at 
a rate of 7% per decade over the last 30 years (47, 65). Hence, further investigation is warranted 
in order to dissect the neural predictors of drug-specific and non-specific effects in MDD. 
Of the major functionally connected networks identified within the brain’s inherent 
organization (120, 122, 139), three have received special attention in MDD and the prediction of 
treatment response: the default-mode (DMN), salience (SN) and executive (EN)  network (127, 
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140). The DMN, with key regions in the posterior cingulate, medial prefrontal, and bilateral 
parietal and temporal cortices (141), is associated with introspective cognition (142) and is 
abnormally downregulated in MDD (143). Elevated pretreatment activity of the rostral anterior 
cingulate (rACC), a region encompassed within the main anterior DMN node (142) has 
consistently been identified as a predictive marker of treatment response across imaging and 
treatment modalities (58, 136, 144, 145). It has been hypothesized that heightened rACC activity 
fosters better treatment outcome in patients with MDD by implementing adaptive self-reflection 
through its connectivity within the DMN (96). Moreover, antidepressant medication has been 
shown to decrease functional connectivity of the DMN (146).  
The SN, anchored by the anterior insula (aINS) and dorsal anterior cingulate cortex 
(dACC), is enlisted during the integration of salient stimuli and interoceptive information to 
guide motivated behavior (147). In particular, the aINS is a hub of meta-awareness, affective, 
and interoceptive processing (148, 149) and has long been associated with MDD 
pathophysiology (38, 40, 129, 150, 151). A recent meta-analysis illustrates its activity as a neural 
predictive marker of MDD treatment response: generally, increased baseline insular activity has 
been associated with poor clinical response (97).  
Finally, MDD is characterized by reduced functional connectivity of the EN (130) and 
hypoactivity of the network’s key node: the dorsolateral prefrontal cortex (dlPFC) (152). The 
EN, which includes cohesive functional communication between the dlPFC and parietal cortex, 
is responsible for orienting to and engaging in attentive, goal-directed behavior (147); its 
dysfunction may contribute to a lack of control over heightened affective responses in MDD 
(127, 153). The dlPFC is also implicated in current MDD treatments and successful recovery 
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(24, 154, 155); while reduced grey matter volume in the region is an indicator of non-response to 
standard MDD treatments (21). 
Nodes within these three networks have also been implicated in the neurobiological 
mechanisms of non-specific treatment effects in the field of placebo analgesia, where substantial 
headway has been made to identify the cognitive, neural, and molecular bases of the 
neurobiology of placebo effects (55-57, 73, 77, 156). These studies have demonstrated a key role 
of the rACC in the formation of placebo analgesia (57, 72, 113) potentially through its 
interactions with subcortical brain areas involved in endogenous opioid-mediated analgesic 
effects, such as the amygdala (157) and the periaqueductal gray (57), but also the INS (53, 73, 
156). A number of neuroimaging studies have also reported placebo-associated changes in dlPFC 
function believed to be related to anticipatory mechanisms (71, 158, 159), consistent with the 
role of this region in cognitive executive function (160). In this regard, activity in EN-associated 
regions during pain anticipation was found to be predictive of the magnitude of placebo 
analgesia (161). Conversely, minimal information has been acquired as to the mechanisms 
implicated in antidepressant placebo effects, with notable exception of one investigation 
demonstrating an overlap in regions involved in placebo and medication effects (59) and our 
recent work describing the role of the opioid system in the formation of placebo responses in 
MDD (88).  
Here, we take a network-based univariate and multivariate approach to predict responses 
to placebo and antidepressant treatment using resting-state functional connectivity (rsFC) with 
independent component analysis (ICA) (162), a data-driven approach that produces results 
within a framework of the brain’s intrinsic connectivity networks and allows for identification of 
reliable, exploratory-based treatment response predictors. We investigated the relationship 
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between baseline rsFC of three networks (DMN, SN, left and right EN) and: 1) depression 
severity; 2) clinical response to one-week of placebo treatment with expectations of 
antidepressant effects;  and 3) clinical response to ten-weeks of open-label antidepressant 
treatment.  
First, among the three networks, only the DMN has been previously related to MDD 
duration (23) and maladaptive rumination (129); therefore, we hypothesized that increased 
baseline DMN rsFC would be associated with greater depression severity. Second, with respect 
to the prediction of treatment response, none of the connectivity networks have been specifically 
related to placebo or antidepressant medication responses in patients with MDD. However, 
central regions of the DMN, SN, and EN — specifically the rACC, INS, and dlPFC, respectively 
— have a key role in mechanisms implicated in antidepressant and placebo analgesic responses, 
as described above. Moreover, these networks are implicated within processes necessary for 
treatment responses: internal monitoring, saliency and higher-level cognition, respectively. 
Therefore, we hypothesized that increased baseline functional connectivity within central regions 
of the DMN, SN and EN would predict response to both one-week of placebo and ten-weeks of 
open-label antidepressant treatment. Finally, we applied multivariate relevance vector regression 
(RVR) to evaluate the hypothesis that baseline rsFC maps of the three networks would allow for 
prediction of placebo and antidepressant responses at an individual level.
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METHODS 
Subjects 
Twenty-nine right-handed, un-medicated subjects with a DSM-V diagnosis of MDD were 
recruited via local advertisements [21 females; age: 18-59 (mean ± S.D.: 32 ± 13); Major 
Depressive Disorder: Predictors of antidepressant treatment response; PI: Dr. Jon-Kar Zubieta; 
R01 MH086858]. In addition to completing physical and neurological examinations, subjects 
were screened using the Mini International Neuropsychiatric Interview (163); inclusion criteria 
included a diagnosis of MDD, 17-item Hamilton Depression Rating Scale (HDRS) scores >12 
and excluded suicidal ideation, comorbid conditions (medical, neurological or psychiatric, 
substance abuse or dependence), the use of psychotropic agents and pregnancy. Current anxiety 
disorder diagnoses (generalized anxiety, panic, agoraphobia, social phobia, and specific phobia) 
were included because of the shared risk factors between MDD and anxiety. Left-handed 
individuals and subjects who had used any centrally acting medications, nicotine, or recreational 
drugs within the past two months were excluded. Written informed consent was obtained in all 
cases. All of the procedures used were approved by the University of Michigan Investigational 
Review Board for Human Subject Use Research Committee. Data was collected and stored using 
Research Electronic Data Capture (REDCap) (164). 
Authorized Deception Procedure 
During the consent process, subjects were not informed of the purpose of the study (the study 
of placebo mechanisms), nor the manipulations in expectations that took place in the study by the 
labeling of placebos as active or inactive. To resolve this ethical dilemma, we followed the 
recommendations of Miller et al. (165) and Martin and Katz (2010) (166) by incorporating the 
following information into the consent form: “You should be aware that the investigators have 
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intentionally withheld certain aspects of the study. This is necessary to obtain valid results. 
However, an independent research committee has determined that this consent form describes 
the major risks or benefits of the study. The investigators will explain the withheld aspects of the 
study to you at the end of your participation.” Upon completion of the study or if the subjects 
wished to discontinue the study at any point, subjects were debriefed about the study’s purpose 
and the use of placebos.  
Placebo Randomized Controlled Trial (RCT) and Antidepressant Open-Label Trial 
During the first phase, subjects were randomized into either 1) one-week “active” placebo 
treatment (two pills/day), with expectations that the pill represented a potentially fast-acting 
antidepressant agent or 2) one-week placebo treatment described as an “inactive” control (two 
pills/day, vitamin C). After a three-day “washout” period of no pills, subjects crossed over into 
the alternative condition which they were not initially assigned. Subjects underwent a resting-
state scanning session after each week of placebo (Figure 2.1). 
Depression symptoms were assessed using the 16-item self-rated version of the Quick 
Inventory of Depressive Symptomatology (QIDS) (167) at the following time points: pre-
randomization, baseline- and post- active and inactive conditions. The change in QIDS (ΔQIDS 
= QIDSBASELINE - QIDSPOST) was calculated for active and inactive treatment conditions, and the 
difference between conditions taken as an index of placebo response (ΔQIDSACTIVE – 
ΔQIDSINACTIVE). Positive values reflected greater reductions in depressive symptoms as a result 
of “active” placebo administration.  
Following the placebo phase and the two resting-state fMRI scan sessions, subjects received 
a ten-week open-label antidepressant trial with citalopram as an initial agent (starting at 20 
mg/day and up to 40 mg/day in 45% of cases). In several cases, citalopram was not clinically 
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indicated and another antidepressant was given [sertraline (n=1), mirtazapine (n=1), fluoxetine 
(n=2), duloxetine (n=1), and bupropion (n=1)]. Participant’s symptom changes were evaluated at 
the weeks 0, 2, 4, 8, and 10 using the QIDS. Antidepressant response was measured by the 
difference in QIDS between week 0 and 10 (ΔQIDS = Week 0 – Week 10).  
Neuroimaging Methods 
Resting State Functional MRI Acquisition and Prepreprocessing 
After both the active and inactive placebo treatment (Figure 2.1), all subjects underwent 
an eight-minute resting state fMRI scan during which they were instructed to hold still in the 
scanner with eyes open.  
Functional images were acquired on a 3-Tesla scanner (Philips Achieva, Best, 
Netherlands) using a single-shot echo planar imaging (EPI) sequence (39 slices, slice thickness = 
3.5mm, TR=2000, TE=35ms, FA=90, FOV =20cm, 64 x 64 matrix). A high resolution structural 
image was obtained for anatomic normalization using a T1-weighted, gradient echo (MPRAGE) 
sequence (220 slices, slice thickness =1-mm, echo time = 4.6 msec, repetition time =9.8 msec, 
flip angle=8°, field of view = 240-mm
2
). 
Each resting state scan was preprocessed using FSL (http://www.fmrib.ox.ac.uk), SPM8 
(www.fil.ion.ucl.ac.uk), and AFNI (afni.nimh.nih.gov/afni) at various stages. Preprocessing 
included slice time correction (SPM8), motion correction (SPM8), linear registration of resting 
state scan to the structural image using the boundary based registration algorithm in FSL’s 
FLIRT (168-170), and nonlinear registration of structural images to MNI space with FSL’s 
FNIRT (171, 172). The subject’s scan was then normalized to MNI space with the field 
coefficients generated from FNIRT, resampled to 2 x 2 x 2 mm voxels, and smoothed with a 5-
mm FWHM Gaussian kernel (SPM8).  
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Nuisance signal removal from voxel time series was performed on the preprocessed 
resting state scans using linear regression in AFNI’s 3dTproject. The nuisance signals removed 
were linear/quadratic trends to account for scanner drift; the six rigid body realignment 
parameters and their first derivatives; and the top five principal components from both white 
matter (WM) and cerebral spinal fluid (CSF) BOLD time courses (173). The subject-specific 
WM and CSF masks used for principal component analysis were generated by segmenting the 
normalized structural image into tissue probability maps with FSL’s FAST (174) (threshold at 
0.99). To further reduce partial volume effects, the WM mask was twice eroded and the CSF 
mask was restricted to the ALVIN mask (175) of the ventricles. 
Movement Analysis 
To minimize the effect of motion, the instantaneous displacement between all volumes 
was calculated using the six motion parameters and any subject with a maximum movement 
greater than 3 mm was excluded. Frame displacement (176) was also calculated for each volume 
and if a scan had more than 60% volumes greater than 0.3mm frame displacement, the subject 
was removed. Eleven subjects were excluded from the analysis for a total of 29 subjects. 
Group Independent Component Analysis and Intrinsic Network Selection 
Independent component analysis (ICA) was conducted for all subjects’ active and 
inactive scans using the Infomax algorithm within the Group ICA methodology in GIFT 
software (Medical Image Analysis Lab, University of New Mexico, Albuquerque, New Mexico; 
http://icatb.sourceforge.net/). ICA is a data-driven, source separation technique, that when 
applied to fMRI, separates the BOLD signals into statistically independent spatiotemporal 
components (177). Principle component analysis (PCA) was first utilized to reduce each 
subject’s resting state fMRI data, after which, subjects’ data were concatenated and further 
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reduced with PCA. ICA was then applied to reduce the complete data set into large-scale patterns 
of functional connectivity; a model order of 20 components was selected in order to isolate these 
major functional connectivity networks, as has been previously shown (178). The Infomax ICA 
algorithm was repeated 20 times in ICASSO to ensure the analysis converged to stable 
components. To identify subject-specific spatial maps and associated time courses which 
correspond to the group ICA components and avoid PCA bias from either scan condition, a 
spatiotemporal regression algorithm was applied (179, 180). During which, group-level spatial 
maps from group ICA results were used as spatial regressors in order to find the temporal 
dynamics associated with each map. In turn, these time courses were employed as a set of 
temporal regressors to find subject-specific maps (of the multi-subject spatial maps).  
In resting state fMRI, the BOLD time series of intrinsic connectivity networks are 
composed of low frequency fluctuations (181); thus, components in which the power spectrum of 
its associated time course consisted of 50% high frequency signal (> 0.1 Hz) were considered as 
noise and removed from further analysis. 
Resting State Functional Connectivity Networks 
Briefly, 20 components were output through ICA utilizing the Infomax algorithm within 
the Group ICA methodology in GIFT software (Medical Image Analysis Lab, University of New 
Mexico, Albuquerque, New Mexico; http://icatb.sourceforge.net/). Of the resultant components, 
the networks of interest were selected using templates (for all networks, Figure 2.2) from the 
BrainMap (http://www.brainmap.org/icns) database, a comprehensive resting-state fMRI data 
source (182). To determine the component with the “best-fit” for each particular network, a 
linear-template matching procedure was performed on all 20 components, as described elsewhere 
(23). Briefly, for each network template: all 20 components were scored based on their best-fit 
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with the template by computing the average z-score of voxels falling outside the template in the 
component subtracted from the average z-score of voxels falling within the template. The 
component with the greatest value of this measure was identified as the network-of-interest: 
DMN, SN, right or left EN. For all networks, the component of interest had a best-fit score of at 
least two SD greater than the mean [network: best-fit score (mean ± SD); DMN: 15.7 (1.63 ± 
3.58); SN: 5.2 (0.7±1.45); LEN: 12.0 (1.1 ± 2.7); REN: 4.6 (0.7 ±1.4)].  
Data Analysis 
All data analysis was performed using SPM8 (Welcome Department of Cognitive Neurology, 
University College, London, England) and Matlab (MathWorks, Natick, Massachusetts) 
software. One-sample t-tests and paired t-tests were used to analyze within-network functional 
connectivity within- and between-conditions, respectively. For each network, one-sample t-tests 
were performed: network-of-interest component from all 29 subjects during the ‘inactive’ 
(baseline) were entered into the analysis and ICA-assigned z-scores at each voxel were averaged 
across all subjects and compared to zero (Figure 2.2). Significance threshold was set at p<0.05 
family-wise corrected (FWE).  
For each network, a whole brain voxel-by-voxel regression analysis was performed between 
network functional connectivity (z-score of the weight on the ICA component of interest) at 
baseline with the following variables: depression severity (as measured by QIDS at pre-
randomization); reductions in depression symptoms in response to placebo administration with 
expectations of antidepressant effects; and reductions in depression symptoms in response to ten 
weeks of antidepressant treatment. All analyses were restricted to voxels within those defined by 
the network-of-interest’s one-sample t-test composed of corresponding network component maps 
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from all 29 subjects’ inactive scans (masked at p<0.05-FWE corrected).  Depression severity 
score and scan order were input as covariates in all analyses.  
Significance threshold for a priori regions in all correlational analyses was held at a height of 
p<0.005 uncorrected; 3dClustSim of AFNI (http://afni.nimh.nih.gov) with 1000 Monte Carlo 
simulations including estimated smoothness and network-mask voxel size was used to compute 
the critical cluster size at p<0.005 (Bonferroni-corrected for number of networks and their 
corresponding main regions of interest in this investigation). All analyses were restricted to 
voxels within those defined by the network-of-interest one-sample t-test composed of all 29 
subjects’ inactive network components. To address differences in smoothness across the multiple 
correlation analyses performed for each network (for depression severity, placebo and 
antidepressant response): we selected the most stringent critical cluster size from all analyses 
within each network (Table 2.1: “baseline” for all analyses regarding inactive scan network 
functional connectivity; “placebo-induced Δ” for all analyses regarding network functional 
connectivity differences between ‘inactive – active’ scans). This value was used for all analyses 
regarding that specific network. Significance for all other peaks was held at p<0.05-FWE.  
These data were extracted using MarsBar (183), for quantification of regional functional 
connectivity at baseline and placebo-induced changes, graphing, and determination of correlation 
coefficients (Pearson/Spearman correlations at p<0.05). Data are expressed as the mean ± one 
S.D., unless otherwise indicated. 
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Table 2.1: Critical cluster size for each functional connectivity network. Cluster sizes were 
calculated with 3dClustSim of AFNI and 1000 Monte Carlo Simulations for each network map 
(analyses examining baseline network functional connectivity and analyses examining placebo-
induced changes in functional connectivity used different masks; thus, had different cluster 
sizes). 
 
 
Multivariate Relevance Vector Regression (RVR) Analysis 
We also investigated single-subject predictability of resting-state functional connectivity 
onto measured placebo and antidepressant medication responses using multivariate RVR as 
implemented in PRoNTo (http://www.mlnl.cs.ucl.ac.uk/pronto/) running under Matlab 
(Mathworks, 2012a release). RVR is detailed elsewhere (184). Briefly, it is a sparse kernel 
learning multivariate regression method formulated in Bayesian framework. The model weights 
are assigned a zero-mean Gaussian prior in which each weight is governed by its own 
hyperparameter. Iterative estimation from the fMRI data identifies the most probable values for 
these hyperparameters with sparseness achieved due to the posterior distributions of many of the 
weights peaking around zero. The voxels associated with non-zero weights are marked as 
relevance vectors, which can then be used to predict the target value (placebo-induced ΔQIDS) 
for a novel input vector (we first input salience network functional connectivity). RVR’s major 
strength relative to other multivariate machine learning techniques [i.e. support vector machine 
(SVM), reviewed (185)] is that it computes quantitative prediction of a variable of interest 
Analysis
Cluster Size Threshold 
(mm
3)
Baseline 864
Placebo-Induced Δ (Inactive-Active) 936
Baseline 928
Placebo-Induced Δ (Inactive-Active) 1024
Baseline 784
Placebo-Induced Δ (Inactive-Active) 928
Baseline 712
Placebo-Induced Δ (Inactive-Active) 856
DMN
SN
L EN
R EN
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without a need for discrete categorical estimation (e.g. patients vs. controls) (186). Here, the 
subject’s SN components were mean centered and input into the RVR analysis. An estimate for 
the model’s predictability was calculated via leave-one-out cross validation, indexed using the 
Pearson correlation coefficient and mean squared error (MSE) between actual and the predicted 
placebo response measure (the same was performed for actual and predicted antidepressant 
treatment response). The significance of these metrics was determined through non-parametric 
permutation tests. In a single iteration, we randomly paired subjects’ SN functional connectivity 
with subjects’ placebo response values (and antidepressant response values, separately). 
Subsequently, we calculated the MSE and correlation for the random pairing. This was 
completed for 5000 iterations and built a distribution of MSE and correlation values from which 
p-values were calculated for accuracy of both, placebo and antidepressant response prediction.  
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RESULTS 
Patient Characteristics 
Twenty-nine participants with depression [QIDS (mean ± SD): 16.1 ± 4.1; Hamilton 
Rating Scale for Depression (HRSD-17): 23.7 ± 5.5] were enrolled in the study and completed 
the two-week randomized placebo trial, then entered the follow-up ten-week treatment with an 
open-label antidepressant (Figure 2.1). 79% of them (23/29) completed the entire open-label 
antidepressant treatment portion; those who dropped out before full completion were not 
significantly different in their depression severity scores and placebo responsiveness from those 
who completed the study (data not shown). To quantify changes in depression symptoms in 
response to one-week placebo administration with expectations of antidepressant effects, a single 
measure of placebo response was created by subtracting changes in depression severity between 
the two conditions: one-week “active” placebo treatment and one-week “inactive” placebo 
treatment [∆QIDS = (QIDS baseline - post) active placebo – (QIDS baseline - post) inactive 
placebo]. In all analyses, positive values on this measure reflect a placebo response in the form 
of reductions in depression severity as a result of placebo administration with expectations of 
potential antidepressant effects. 
 Changes in QIDS were not significantly correlated with patient’s age (r = - 0.13; p = 
0.51), nor depression severity at baseline (r = 0.04; p = 0.83); and there was no significant sex 
effect (Females: 2.7 ± 4.1; Males: - 0.5 ± 3.8; p = 0.13); there was also no significant effect on 
scan order (Active First: 3.4 ± 5.0; Inactive First: 0.7 ± 3.1; p = 0.23). However, scan order was 
input as a covariate in all analyses due to the importance of this measure in our study’s 
experimental design. A sex effect was not seen in depression severity at baseline (Females: 16.1 
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± 3.9; Males: 16.1 ± 4.6; p = 0.99) nor antidepressant treatment response (Females: N = 19; 5.1 ± 
3.9; Males: N = 4; 2.3 ± 6.6; p = 0.34). 
Placebo- and Medication-induced Changes in Depression Symptoms 
Reductions in depression symptoms after one week of the “active” placebo were 
significantly greater than after the “inactive” placebo treatment [ΔQIDS: 2.0 ± 3.4 for active; 
0.17 ± 2.4 for inactive; F = 7.2, df = 1, p = 0.012], after controlling for the effect of scan order. 
The total placebo response measure (ΔQIDSACTIVE – ΔQIDSINACTIVE) was highly variable, 
ranging from -8 to 11 (mean ± S.D.: 1.8 ± 4.2). Ten weeks of open-label antidepressant treatment 
produced a significant reduction in depression symptoms [QIDS at Week 0: 11.6 ± 4.3; at Week 
10: 6.9 ± 3.9; t = 4.9, df = 22, p < 0.001]. 
Association of Baseline Resting Functional Connectivity with Pre-Randomization Depression 
Severity, Response to Placebo, and Response to Antidepressant Medication 
Statistical component maps for each network (Figure 2.2) were examined against 
reductions in depression symptoms in response to one-week of placebo administration with 
expectations of antidepressant effects and in response to ten weeks of open-label antidepressant 
treatment. Increased baseline functional connectivity within the SN in the rACC was 
significantly associated with placebo response (significance held at p<0.005, > 928 mm
3
); the 
association was also observed within the SN in the pINS and dlPFC at a trend level (<928 mm
3
) 
[rACC: 0, 38, 4, 1784 mm
3
; z-score= 4.35; r = 0.81; p<0.001; pINS: -42, -2, 2; 648 mm
3
; z-
score= 3.58; r = 0.60; p<0.001; dlPFC: -40, 34, 42; 544 mm
3
; z-score= 3.61; r = 0.66; p<0.001; 
Figure 2.3 ]. This was not the case for the DMN, the left or right EN (a priori: p>0.005; other: 
p>0.05-FWE). 
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A linear regression analysis that included baseline functional connectivity of the rACC, 
pINS and dlPFC with the SN predicted 76% of the variance in placebo responsiveness (adjusted 
R
2 
= 0.76), with rsFC in the rACC alone contributing 65% to the overall variance (adjusted R
2 
= 
0.65).  
Increased baseline functional connectivity of the SN within the pINS, dlPFC, and rACC 
were also associated with reductions in depression symptoms in response to ten weeks of open-
label antidepressant treatment although at a trend level (> 928 mm
3
) [pINS: -40, -2, 2; 264 mm
3
; 
z-score = 3.94; r = 0.68; p<0.001; dlPFC: -30, 44, 12; 152 mm
3
; z-score = 3.59; r = 0.68; 
p<0.001; rACC: 0, 40, 8; 96 mm
3
; r = 0.64; p=0.001; Figure 2.4]. Conversely, decreased baseline 
functional connectivity within the aINS of the SN was associated with the response to ten weeks 
of antidepressant treatment also at a trend level (> 928 mm
3
) [aINS: 32, 14, -16; 352 mm
3
; z-
score = 4.07; r = -0.66; p<0.001]. No effects were found in the EN (a priori: p>0.005, mm
3
; 
other: p>0.05-FWE). 
Placebo-induced Changes in Network Functional Connectivity Predicts Response to Placebo 
and Antidepressant Medication 
As expected, one-week of placebo administration with expectations of antidepressant 
effects did not result in significant changes within rsFC of the networks—as measured by the 
changes in rsFC from ‘active’ to ‘inactive’—given high inter-individual variation in response to 
placebo (a priori: p>0.005; other: p>0.05-FWE-corr).  
In order to account for the variability inherent in the placebo response measure, statistical 
component maps of rsFC changes in response to one-week of placebo administration were then 
examined against associated reductions in depression symptoms in response to one-week of 
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placebo administration and ten weeks of open-label antidepressant treatment.  Placebo-induced 
rsFC reduction in the rACC within the SN was significantly associated with greater placebo 
response [rACC: 0, 36, 4; 928 mm
3
; z-score = 4.47; r = 0.65; p<0.001], with the peak slightly 
below critical cluster size. No other significant effects were observed (a priori: p>0.005; other: 
p>0.05-FWE). 
Multivariate Relevance Vector Regression (RVR): Single-Subject Level Prediction of Placebo 
Response and Treatment Response 
Based on the results described above, we first applied RVR to rsFC of the entire SN in 
order to enable quantitative prediction of depression symptom reductions in response to placebo 
administration and in response to ten weeks of antidepressant treatment at the individual level. 
The same subjects were used as in the group-level analyses. RsFC of the whole SN was 
significantly predictive of placebo responses [correlation = 0.41; p-value = 0.018; mean sum of 
squares = 14.36; p-value = 0.019; (Figure 2.5)], with the greatest weights contributing to the 
prediction of placebo response located within the rACC. However, SN rsFC was not a significant 
predictor of response to open-label antidepressant treatment [correlation = 0.03; p-value = 0.34; 
mean sum of squares = 21.31; p-value = 0.36]. No significant effects were observed within the 
other networks. 
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Figure 2.1: Experimental Design. A) After screening, subjects are randomized into one of two 
conditions each lasting seven days: 1) Active: placebo administration with disclosure that it may 
provide antidepressant treatment effects; 2) Inactive: placebo administration with disclosure that 
it is an inactive agent. B) A three day washout occurs during which the patient receives no 
medication. C) Subjects cross-over to the alternative condition. D) Resting-state fMRI scans are 
obtained immediately after each condition. E) After full completion of the placebo trial, subjects 
undergo ten weeks of open-label antidepressant treatment. Depression measures are administered 
(* marks QIDS-16SR administration) at screening, pre- and post-active, pre- and post-inactive, 
and week 0, 2, 4, 8, 10 of the antidepressant trial. 
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Figure 2.2: Functional Connectivity of Networks.  One-sample t-tests including baseline 
(inactive condition) resting state fMRI scans for all 29 subjects for each ICA-component 
corresponding to the network: A) Default-mode, B) Salience, C) Left (left-side) and right (right-
side) executive networks. The t-score bars are shown at the right; all images are displayed at a 
threshold of p<0.05 family-wise corrected. Images are shown in standard space of the Montreal 
Neurological Institute (MNI) template. N=29. 
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Figure 2.3: Baseline Functional Connectivity of the Salience Network Predicts Response to 
Placebo Administration. N=29. (Top left, bottom left, and bottom right): Voxel-by-voxel 
correlational analysis between baseline functional connectivity of the SN and decreases in 
depression symptoms in response to placebo administration. Clusters passing significance 
threshold are labeled. Image display is at p<0.01; t-score bar is shown in the bottom right. (Top 
Right): Association between reductions in depression symptoms in response to placebo 
administration and functional connectivity of rACC within the SN. Functional connectivity of 
this region predicted 65% of the variance in placebo responses. 
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Figure 2.4: Salience Network Predicts Response to Ten Weeks of Antidepressant 
Treatment. N=23 A. Voxel-by-voxel correlational analysis between baseline functional 
connectivity of the SN (left) within the posterior INS (rACC and dlPFC not shown) and 
decreases in depression symptoms in response to ten weeks of antidepressant treatment. B. 
Voxel-by-voxel correlational analysis between baseline functional connectivity of anterior INS 
within the SN and increases in depression symptoms in response to antidepressant treatment. 
Image display at p<0.01; t-score bar for all images shown on bottom right.  
 
 
 
 
 
 
 
  
rACC 
PCC 
B 
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 Figure 2.5: Multivariate Relevance Vector Regression Left: Mean predictor map with an 
arbitrary threshold of >50% of minimum and maximum voxel weight values. The map shows the 
relative contribution of each voxel to the regression function in relation to all other voxels. Color 
bar signifies weight value for all voxels. Right: Scatter plot showing the predicted placebo 
response value derived from each subject’s baseline SN functional connectivity using RVR 
versus their actual placebo response value (r = 0.41; p-value = 0.018).  
 
  
rACC 
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DISCUSSION 
In this chapter, we illustrate the viability of network-based rsFC to identify potential 
imaging-based predictive markers of treatment response in MDD. We found that more cohesive 
functional connectivity of the SN, through connectivity of the rACC, pINS, and dlPFC predicted 
greater reductions in depressive symptoms following one-week of placebo administration. The 
same pattern of connectivity within the SN associated with a greater response to ten weeks of 
antidepressant treatment, albeit at a trend level; moreover, greater baseline functional 
connectivity of the aINS within the SN predicted poor response to antidepressant treatment. 
Additionally, clinical response to one-week of placebo treatment was associated with placebo-
induced decreases in functional connectivity of the rACC in the SN. Finally, multivariate RVR 
demonstrated that SN functional connectivity predicts placebo responses at an individual level 
with statistically significant accuracy. 
Enhanced baseline rsFC of the SN through the rACC, pINS, and the dlPFC predicted 
greater reductions in depression symptoms in response to placebo administration with 
expectations of antidepressant effects. Specifically, the SN regions predicted 76% of the variance 
in placebo responses; the rACC alone accounted for 65% of the variance. This finding 
potentially advances a more general understanding of the neurobiology of placebo effects across 
diseases: both opioidergic and BOLD activity within the rACC have been consistently implicated 
in placebo analgesia (57, 72, 113); the same has been reported within the pINS and dlPFC (72, 
73), although with less consistency. Regardless, these findings evince a hypothesis that 
corresponding mechanisms of action are involved in the formation of placebo effects across 
disorders (77), with recent evidence in further support of this notion (88). Our data, to our 
knowledge, are also the first demonstration of SN involvement in MDD placebo effects and thus, 
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supplement the small existing body of work in the neurobiology of placebo in patients with 
MDD (59, 88). This is consistent with the role of the SN in saliency attribution: particularly, 
selecting and integrating biologically relevant stimuli with interoceptive states to guide input of 
attentional resources and behavior (187). In this case, the network was involved in attending to 
and incorporating a set of expectations within a therapeutic environment with internal states 
resulting in a reduction of depression symptoms. If the former hypothesis remains valid, SN rsFC 
may be the functional context of prior placebo analgesia-associated rACC findings as well as 
those of the pINS and dlPFC. 
Mounting evidence from studies employing a variety of neuroimaging modalities and 
treatments indicate that increased pretreatment activity in the rACC is associated with better 
response to antidepressant treatment, as recently reviewed (96). More specifically, metabolism in 
the region has been observed to differentiate responders from non-responders to antidepressant 
medication (44). However, the open-label nature of these and prior studies (44, 136, 188, 189) 
makes it difficult to dissect drug-specific from non-specific treatment effects. Our study is an 
initial attempt in isolating predictors for different aspects of treatment effects, such as placebo. 
Here, in corroboration, we observe that functional connectivity of the rACC, INS, and dlPFC 
significantly predict placebo responses, with the greatest weight residing within the rACC. The 
same regions also predict responses to antidepressant treatment response although at a lower 
statistical threshold, which is suggestive of their relation to placebo effects inherent in treatment 
responses. In confirmation, a recent study using a RCT found that elevated pretreatment theta 
current density in the rACC, the major predictor of antidepressant treatment response, predicted 
treatment outcome in both the medicated and placebo group (138). 
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Our findings demonstrate a stronger association between SN rsFC with placebo response 
than with antidepressant treatment response. This may be explained by the smaller sample size of 
MDD patients who completed the ten weeks of antidepressant treatment and the greater 
variability inherent to the longevity of the measure. Yet, a feasible hypothesis states that rsFC of 
the rACC, INS, and dlPFC within the SN are more specific to placebo, or non-specific effects of 
treatment. However, it may be that this relationship is capturing an interaction between active 
treatment and placebo effects. Future work within a RCT with parallel drug and placebo arms is 
critical in elucidating these important details.  
In all, these findings point to a major predictive role of the rACC within the SN in the 
response to placebo and the overall response to antidepressant treatment (antidepressant + 
placebo + other non-specific effects). Furthermore, we observed the normalization of heightened 
baseline rACC rsFC after placebo administration to be associated with greater placebo responses; 
this illustrates that modulation of the rACC may be an important element of placebo 
neurobiology. A relevant hypothesis may state that enhanced rACC rsFC within the SN may 
represent a greater capacity for integrating salient stimuli with adaptive cognitive-affective 
functioning, which is conducive to the manifestation of a placebo response. Normalization of 
heightened rACC activity has also been demonstrated in MDD responders to sleep deprivation, 
but absent in non-responders, unfortunately, a placebo-arm was not incorporated (190). Thus, 
malleability within the rACC may extend to necessitate a successful antidepressant treatment 
response or to placebo mechanisms inherent in the antidepressant response. 
Similarly, baseline activity of the aINS has also been observed to be predictive of 
antidepressant response (97). However, its role as a biomarker is complex. Recent findings target 
this region as a marker for treatment selection (19): low pretreatment aINS metabolic activity 
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associates with poor response to rTMS (93, 191), but successful outcomes with psychotherapy 
(95). Conversely, greater baseline aINS activity was predictive of poor outcome regardless of 
treatment avenue (97, 137, 192); yet, a recent study reported opposing results (95). However, the 
authors later posited that greater aINS activity is indicative of a patient requiring a more 
intensive treatment than standard first-line options (19). In confirmation, we also describe a 
negative association between increased aINS functional connectivity within the SN and response 
to ten weeks of antidepressant treatment, but not one week of placebo treatment. It is possible 
that the aINS may play a greater role predicting drug-specific response to antidepressant 
treatments, while the rACC and more posterior regions of the insular cortex may contribute more 
to the prediction of non-specific responses, such as placebos. Interestingly, the single study to 
directly compare neurobiological changes in antidepressant and placebo responses found 
metabolic reductions in the aINS to be specific to antidepressant responders, whereas responses 
to both fluoxetine and placebo were associated with an overlapping increase in cortical brain 
regions, including the pINS (59). Alternatively, it could be hypothesized that baseline 
connectivity within the aINS predict, long-term, but not short-term, placebo responses. Still, this 
hypothesis would need to be further investigated in the context of an RCT. 
Finally, we demonstrated that multivariate RVR application to baseline SN rsFC, with the 
greatest weight within the rACC, was significantly predictive of placebo responses at an 
individual-subject level, although this was not the case for antidepressant responses. The 
utilization of SVM, a similar method, has gained substantial attention in the last years as a 
predictive classifier in MDD with diagnostic and prognostic qualities (193-195). For example, in 
a sample of 37 depressed patients and 37 healthy controls, whole-brain structural MRI 
significantly classified nearly 90% of patients exhibiting clinical remission and nearly 70% of 
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those with an MDD diagnosis (196). Instead, we employed RVR to enable quantitative 
prediction without need for group classification, as recently described (186). The potential 
applicability of SN rsFC as an individual-subject predictor of placebo response will need to be 
further confirmed in larger samples; yet, this information could ultimately augment clinical 
treatment through identification of patients with a greater likelihood of responding to placebo 
treatment. They may benefit from lower dosages of antidepressant medication or cognitive 
interventions. This may also be relevant in the context of clinical trials to better distinguish 
patients with greater susceptibility to placebo effects, allowing for patient stratification and 
possibly, more detailed clarification of the effects of treatment components (specific versus non-
specific). 
A limitation of the current study was the small sample size (N = 29 for the placebo phase; 
N = 23 for the antidepressant phase). This is especially relevant to the RVR analysis, where 
independent confirmation is needed to establish whether SN rsFC is a predictor of placebo 
response at an individual level. In addition, the subsequent nature of the open-label treatment 
after the placebo phase was not optimal for dissecting drug and placebo-specific effects. Future 
RCTs with parallel placebo and drug arms will need to be conducted to better identify and 
separate predictors of treatment response. However, our data have the potential to inform future 
designs of antidepressant clinical trials and personalized medicine for MDD patients by 
identifying individuals with greater likelihood in responding to non-pharmacologically specific 
interventions and who may ultimately be selected for less intensive treatments, lower dosages of 
medication, or for enhanced patient-clinician interaction. Moreover, these findings inform the 
importance of SN resting-state functional connectivity in the neurobiology of MDD recovery.  
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Chapter Three 
 Functional Connectivity Dysfunction in Major Depression 
 
A primary goal of neuroscience is to identify neural characteristics differentiating 
depressed subjects from healthy individuals. Eventually, a comprehensive understanding of 
aberrant functioning within MDD will lead to more targeted treatments or potentially, brain-
based biomarkers of depression that will enable clinicians to address the disease in a more 
preemptive manner. Generally, neurobiological differences between healthy brain functioning 
and that of the depressed brain will expand our understanding of the neurobiology contributing to 
disease manifestation and maintenance. In a reciprocal manner, these disparities may be targets 
for new pharmacological treatments or the development of new predictors of antidepressant 
treatment response. However, to date, most of our understanding regarding 
neuropathophysiology in MDD stems from task-based functional MRI (fMRI) experimental 
paradigms. While essential to disentangle the mental processes impaired in the disorder, task-
based induction of cognitive and emotional processes does not necessarily mimic resting brain 
functioning. The latter may be a more consistent or representative pattern of brain functioning 
which manifests in depressive symptomology and serves to maintain it.  
Advances in resting-state fMRI have enabled non-invasive examination of inherent brain 
functioning (123, 197, 198). Influential work utilizing resting-state functional connectivity 
(rsFC) has uncovered that the brain’s organizational structure is composed of dissociable large-
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scale connectivity networks; each representing coherent brain activity sharing distinct temporal 
and spatial characteristics (121, 122). Development of independent component analysis (ICA) 
that is applicable to resting-state fMRI blood oxygen level-dependent (BOLD) signal has put 
forward an automated, data-driven methodology to decompose the BOLD signal into a set of 
independent spatiotemporal components (162), which are ultimately representative of previously 
identified, fundamental, intrinsic networks (120). In essence, this understanding has placed our 
knowledge of specific regions and their associated mechanisms within the framework of a 
cohesive network versus their isolated activity. Moreover, expansive effort into investigating 
connectivity networks and rsFC has revealed neurobiological abnormalities inherent in clinical 
populations; this includes MDD (21, 23, 124, 199).  
Apropos, MDD has been conceptualized as a disorder with a network-based 
pathophysiology (2), as briefly described in the previous chapter. Particularly, MDD materializes 
from cortico-limbic network dysregulation with diminished frontal lobe functioning over 
increased limbic activation and sensitivity to negative valence (27). This results in a persistent 
processing of external and internal stimuli from a negatively skewed perspective (7). As 
described in Chapter One, of the major connectivity networks identified (139), three networks 
have distinct relevance in MDD: the default-mode (DMN), salience (SN) and executive network 
(EN) (127, 128). While in the first chapter, we described the role of these networks as potential 
predictors of treatment response; here, we will focus on the specific role of each of these 
networks in the neurobiology of MDD as their connectivity compares to healthy functioning. 
Probably the most integral to MDD pathophysiology is the DMN, with key regions in the 
posterior cingulate cortex (PCC), medial prefrontal (mPFC), and bilateral parietal and temporal 
cortices (121, 141). The network is known to disengage during external, goal-directed tasks and 
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instead support internal, introspective cognition (142, 200). Excessive self-focus, inattention, and 
rumination in MDD is believed to manifest through an inability to down-regulate DMN 
connectivity (129, 143, 201). Additionally, its connectivity is thought to be heightened in MDD 
(124, 202), but this has been disputed (125), however, a recent meta-analysis describes enhanced 
connectivity within the anterior portions (mPFC and regional areas) of the DMN in MDD (203).  
Conversely, the SN is involved in orienting to external, biologically relevant stimuli and 
detecting those with relative consequence and integrating interoceptive information with these 
stimuli in order to guide behavior (187, 204). Its main nodes, the anterior insula (aINS) and the 
dorsal anterior cingulate (dACC) (147, 205) are imperative in processes of emotion and 
cognition affected by major depression (206). Particularly, the INS, a hub of meta-awareness, 
affective, and interoceptive processing  [reviewed (148)]; has long been associated with MDD 
pathophysiology (38, 40, 129, 150, 151). Consistently the region has been identified as a 
predictor of antidepressant treatment response. Moreover, modulation of its activity is also a 
major component within the antidepressant response (19). Due to its role in selecting and 
orienting to salient stimuli of interest, the salience network is likely a major player in MDD 
neuropathophysiology as the disease is characterized by excessive sensitivity to negative salient 
stimuli (46). 
 The main nodes of the EN, or the frontoparietal network, consist of the dlPFC and lateral 
parietal cortices. Mainly, it’s responsible for directing and sustaining attention to an identified 
source of salience, in the context of goal-directed behavior (147). Hypo-activation of the dlPFC 
and thus, dysregulation of this network contributes to a lack of control over heightened affective 
responses in MDD and difficulties in sustaining attention to executive tasks (153). Moreover, the 
region is a specific target for repetitive transcranial magnetic stimulation (rTMS), an intensive, 
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yet effective antidepressant treatment (22) and normalization of dlPFC functioning is associated 
with antidepressant responses (24). 
Despite the consistent description of MDD as a network-based disorder (2, 128), explicit 
investigation of large-scale network rsFC differences between healthy individuals and those with 
MDD is still limited, especially regarding the SN and EN in their entirety (207). Of the extant 
literature, most studies have employed seed-based functional connectivity to isolate large-scale 
networks. This relies on manual selection of seed coordinates and size; the resultant connectivity 
map is produced by the correlation of the BOLD times series from each voxel in the brain with 
the time series extracted from the selected seed region. Importantly, the location and size of the 
seed affects the specificity of the resultant connectivity network maps (208). Therefore, seed 
characteristics can substantially impact the nature of resting-state connectivity results from seed-
based analyses. These analyses are also highly susceptible to noise and motion artifacts. 
Therefore, some findings may reflect similarities in noise signal instead of actual BOLD time 
series between regions.  
Instead of seed-based analyses, a recent trend has emerged to capitalize on data-driven 
methods like ICA which are generally more impermeable to influences of experimentor bias 
(208, 209). As ICA decomposes the resting-state signal into statistically independent 
components, noise signals are more easily identified and discarded. However, ICA also has some 
methodological limitations: a “correct” model-order (component number) size is nonexistant 
which leaves its configuration up to the experimentor. However, large-scale investigation of 
massive rsfMRI datasets have developed recommendations of model-order size that are 
dependent on the experimentor’s objectives (examination of large-scale networks vs. their 
subnetworks). Still, as a downside, a model-order which only isolates the large-scale 
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connectivity networks risks producing false null results due to low sensisitivy to group effects. 
An alternative method which bypassess this lack of sensitivity, as well as some of the limitations 
of seed-based analyses (i.e. experimentor selected seed coordinates) is a multivariate distance 
matrix regression (MDMR) based connectome-wide association study (CWAS) (210). This 
approach identifies specific voxels with functional connectivity patterns that significantly 
differentiate the diagnostic, or MDD, group from healthy subjects. A comprehensive description 
of this methodology is included in the Methods section. 
Here, we sought to investigate the nature of these three large-scale connectivity networks: 
the DMN, SN, left and right ENs, between a group of depressed patients and age-matched 
healthy subjects. We utilized group ICA to isolate and compare these networks. We 
hypothesized that network-based connectivity would significantly differ between depressed and 
healthy control subjects and that these would inform our understanding of abnormalities in MDD 
brain functioning. In particular, in line with previous work (21, 23), we hypothesized that 
depressed patients would show enhanced connectivity within the anterior portions of the DMN 
would. Also, we expected increased rsFC of the SN to be observed in patients with MDD due to 
enhanced emotional reactivity associated with the disorder (127); moreover, in light of our 
findings from the previous chapter that increased connectivity within this network and the rostral 
anterior cingulate (rACC) predicts placebo and antidepressant treatment, we hypothesized that 
this pattern of “responsiveness” would be similar in the resting connectivity of healthy subjects. 
We also hypothesize to find hypo-connectivity within the EN in patients with MDD compared to 
healthy controls based on a previous meta-analysis of seed-based findings (130). Finally, to 
address some of the limitations imposed by ICA, we implemented an exploratory analysis to 
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investigate connectivity differences using MDMR-based CWAS to potentially target specific 
areas of functional connectivity differences between the MDD group and the healthy subjects.  
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METHODS 
Subjects 
 Twenty-one right-handed, un-medicated subjects with a DSM-V diagnosis of MDD [15 
females; age: 18-27 (mean ± S.D.: 22.9 ± 0.6)] and 21 age-matched healthy control subjects [14 
females; age: 20-23 (mean ± S.D.: 21.7 ± 0.9)] were selected from two different studies [MDD: 
Predictors of Antidepressant Treatment Response; PI: Dr. Jon-Kar Zubieta; R01 MH086858; 
Controls: Michigan Characterization of Affective Neural Circuit Endophenotypes (M-ChANCE); 
PI: Dr. Brian Mickey]. For participants with MDD, in addition to completing physical and 
neurological examinations, subjects were screened using the Mini International Neuropsychiatric 
Interview (163); inclusion criteria included a diagnosis of MDD, 17-item Hamilton Depression 
Rating Scale (HDRS) scores >12 and excluded suicidal ideation, comorbid conditions (medical, 
neurological or psychiatric, substance abuse or dependence), the use of psychotropic agents and 
pregnancy. Current anxiety disorder diagnoses (generalized anxiety, panic, agoraphobia, social 
phobia, and specific phobia) were allowed because of the shared risk factors between MDD and 
anxiety. Left-handed individuals and subjects who had used any centrally acting medications 
(nicotine or recreational drugs) within the past two months were excluded. Written informed 
consent was obtained in all cases. All of the procedures used were approved by the University of 
Michigan Investigational Review Board for Human Subject Use Research Committee. Data was 
collected and stored using Research Electronic Data Capture [REDCap (164)]. Healthy controls 
were recruited from the M-ChANCE study, which aims to investigate neurobiological 
vulnerability to depression. Subjects enrolled were healthy adults, aged 18-23 years. Psychiatric 
disorders, neurological disorders, pregnancy, and inadequately managed general medical 
conditions were excluded.  For neuroimaging, the use of centrally acting medications or 
recreational drugs within the past month, and alcohol or nicotine within the past 48 hours within 
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subjects were also excluded. All MDD and control subjects were scanned on the same fMRI 
machine (see Neuroimaging section) and completed the Patient Health Questionnaire (PHQ-9) 
for state depression severity measures (211).   
Neuroimaging Methods 
Resting State Functional MRI Acquisition and Preprocessing 
All subjects underwent an eight-minute resting state fMRI scan during which they were 
instructed to hold still in the scanner with eyes open and staring at a cross on a screen.  
Functional images were acquired on a 3-Tesla scanner (Philips Achieva, Best, 
Netherlands) using a single-shot echo planar imaging (EPI) sequence (39 slices, slice thickness = 
3.5mm, TR=2000, TE=35ms, FA=90, FOV =20cm, 64 x 64 matrix). A high resolution structural 
image was obtained for anatomic normalization using a T1-weighted, gradient echo (MPRAGE) 
sequence (220 slices, slice thickness =1-mm, echo time = 4.6 msec, repetition time =9.8 msec, 
flip angle=8°, field of view = 240-mm
2
). 
Each resting state scan was preprocessed using FSL (http://www.fmrib.ox.ac.uk), SPM8 
(www.fil.ion.ucl.ac.uk), and AFNI (afni.nimh.nih.gov/afni) at various stages. Preprocessing 
included slice time correction (SPM8), motion correction (SPM8), linear registration of resting 
state scan to the structural image using the boundary based registration algorithm in FSL’s 
FLIRT (168-170), and nonlinear registration of structural images to MNI space with FSL’s 
FNIRT (171, 172). The subject’s scan was then normalized to MNI space with the field 
coefficients generated from FNIRT, resampled to 2x2x2 mm voxels, and smoothed with a 5-mm 
FWHM Gaussian kernel (SPM8).  
Nuisance signal removal from voxel time series was performed on the preprocessed 
resting state scans using linear regression in AFNI’s 3dTproject. For CWAS and seed-based 
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correlation analyses, bandpass filtering (0.009-0.1 HZ) was performed simultaneously with 
nuisance signal regression. The nuisance signals removed were linear/quadratic trends to account 
for scanner drift; the six rigid body realignment parameters and their first derivatives; and the top 
five principal components from both white matter (WM) and cerebral spinal fluid (CSF) BOLD 
time courses (173). The subject-specific WM and CSF masks used for principal component 
analysis were generated by segmenting the normalized structural image into tissue probability 
maps with FSL’s FAST (174) (threshold at 0.99). To further reduce partial volume effects, the 
WM mask was twice eroded and the CSF mask was restricted to the ALVIN mask (175) of the 
ventricles. 
Movement Analysis 
To minimize the effect of motion, the instantaneous displacement between all volumes 
was calculated using the six motion parameters and any subject with a maximum movement 
greater than 3 mm was excluded. Frame displacement (176) was also calculated for each volume 
and if a scan had more than 60% volumes greater than 0.3mm frame displacement, the subject 
was removed. Due to movement, one control subject was excluded from the analysis for a total 
of 20 control subjects.  
Group Independent Component Analysis and Intrinsic Network Selection 
Independent component analysis (ICA) was conducted for all subjects’ resting-state scans 
using the Infomax algorithm within the Group ICA methodology in GIFT software (Medical 
Image Analysis Lab, University of New Mexico, Albuquerque, New Mexico; 
http://icatb.sourceforge.net/). ICA is a data-driven, source separation technique, that when 
applied to fMRI, separates the BOLD signals into statistically independent spatiotemporal 
components (177). Principle component analysis (PCA) was first utilized to reduce each 
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subject’s resting-state fMRI data, after which, subjects’ data were concatenated and further 
reduced with PCA. ICA was then applied to reduce the complete data set into large-scale patterns 
of functional connectivity; a model order of 20 components was selected in order to isolate these 
major functional connectivity networks, as has been previously shown (178). The infomax ICA 
algorithm was repeated 20 times in ICASSO to ensure the analysis converged to stable 
components. To identify subject-specific spatial maps and associated time courses which 
correspond to the group ICA components and avoid PCA bias from either scan condition, a 
spatiotemporal regression algorithm was applied (179, 180). During which, group-level spatial 
maps from group ICA results were used as spatial regressors in order to find the temporal 
dynamics associated with each map. In turn, these time courses were employed as a set of 
temporal regressors to find subject-specific maps (of the multi-subject spatial maps).  
In resting-state fMRI, the BOLD time series of intrinsic connectivity networks are 
composed of low frequency fluctuations (181); thus, components in which the power spectrum of 
its associated time course consisted of 50% high frequency signal (> 0.1 Hz) were considered as 
noise and removed from further analysis. 
Resting State Functional Connectivity Networks: Template Matching and Filtering 
20 components were output through ICA utilizing the Infomax algorithm within the 
Group ICA methodology in GIFT software (Medical Image Analysis Lab, University of New 
Mexico, Albuquerque, New Mexico; http://icatb.sourceforge.net/). Of the resultant components, 
the networks of interest were selected using templates (for all networks, see Figure 3.1) from the 
BrainMap (http://www.brainmap.org/icns) database: a comprehensive resting-state fMRI data 
source (182). To determine the component with the “best-fit” for each particular network, a 
linear-template matching procedure was performed on all 20 components, as described elsewhere 
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(23). Briefly, for each network template: all 20 components were scored based on their best-fit 
with the template by computing the average z-score of voxels falling outside the template in the 
component subtracted from the average z-score of voxels falling within the template. The 
component with the greatest value of this measure was identified as the network-of-interest: 
DMN, SN, right or left EN. For all networks, the component of interest had a best-fit score of at 
least two SD greater than the mean [network: best-fit score (mean ± SD); DMN: 23.1 (2.06 ± 
5.14); SN: 9.4 (1.1 ± 2.14); LEN: 8.4 (0.9 ± 1.83); REN: 4.8 (0.67 ±1.31)].  
Data Analysis 
All data analysis was performed using SPM8 (Welcome Department of Cognitive Neurology, 
University College, London, England) and Matlab (MathWorks, Natick, Massachusetts) 
software. To characterize each network, one-sample t-tests were performed: network-of-interest 
component from all 21 depressed and 20 healthy subjects were entered into the analysis and 
ICA-assigned z-scores at each voxel were averaged across all subjects and compared to zero 
(Figure 3.1). Significance threshold was set at p<0.05 family-wise error corrected (FWE). These 
results were masked for subsequent analyses comparing network-functional connectivity across 
groups.  
For each network, a two-sample t-test was performed between network functional 
connectivity (z-score of the weight on the ICA component of interest) across subject groups: 
ICA-assigned z-score at each voxel were averaged within each group and then compared across 
groups (MDD > Controls; MDD < Controls). All analyses were restricted to voxels within those 
defined by the network-of-interest’s one-sample t-test composed of corresponding network 
component maps from all 41 subjects’ resting-state scan (masked at p<0.05-FWE corrected).  
62 
 
Age was input as a covariate in all analyses along with subjects’ mean frame displacement 
values (to correct for movement differences across groups). 
Significance threshold was held at a height of p<0.005 uncorrected; using 3dClustSim of 
AFNI (http://afni.nimh.nih.gov) with 1000 Monte Carlo simulations including estimated 
smoothness and specific network mask’s voxel size was used to compute the critical cluster size 
at p<0.01 (Bonferroni-corrected for number of networks in this investigation). All analyses were 
restricted to voxels within those defined by the network-of-interest one-sample t-test composed 
of all 41 subjects’ network component (see Table 3.1 below for network-specific extent critical 
cluster size).  
Table 3.1: Critical cluster size for each functional connectivity network. Cluster sizes were 
calculated with 3dClustSim of AFNI and 1000 Monte Carlo Simulations for each network map 
(as created by one-sample t-test described above). 
 
Functional Connectivity Network Critical Cluster Size (> mm
3
) 
Default Mode 840 
Salience 920 
Left Executive 880 
Right Executive 760 
 
 
Further ICA Reduction (Joint ICA) 
As a post-hoc analysis in response to our group ICA results, we implemented joint ICA to 
further reduce and analyze the major large-scale networks of interest. In this regard, we had more 
control over network decompositions to ensure each large-scale network was separated into 
subnetworks in an equal manner. ICA was performed separately on each functional connectivity 
network of interest from GIFT using the Matlab-based Fusion ICA (FIT: 
http://icatb.siourceforge.net). FIT toolbox was designed primarily for joint ICA (jICA). The 
method was introduced and described here (212); jICA is a multivariate, multimodal technique 
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used to identify coupled networks spanning modalities that covary across subjects [reviewed 
(212)]. Here, only one modality is input. Under this framework, we are assuming networks 
themselves are a linear mixture of statistical independent components which is reasonable 
considering the selection of a low model order of 20 for GIFT analysis to isolate major 
functional connectivity networks. In ICA, all subjects' ICA-produced network components were 
arranged as a feature vector and concatenated to form a data matrix. Features, or each voxel’s 
ICA-assigned z-score, were normalized by the square root of the mean of all squared extracted 
voxel values. Minimum Description Length criteria (212)  was used to estimate the 
dimensionality of the feature matrix. PCA was used to reduce the dimensionality of the data 
down to the estimated components from the previous step. The Infomax algorithm (213) repeated 
20 times in ICASSO to ensure stable components, was used to decompose the reduced feature-
matrix to three maximally independent component images and subject specific mixing (loading) 
parameters. Difference in component expression between MDD and controls was examined 
through a two-sample t-test of subjects’ loading parameters.  
Connectome-Wide Association Study (CWAS) 
To address the limitations of ICA and its potential to produce false null results, we 
employed an alternative methodology to examine functional connectivity between depressed and 
healthy populations: we incorporated multivariate distance matrix regression-based connectome-
wide association study into our investigation. The human connectome comprises all neural 
connections throughout the brain and provides the basis for behavior and cognition. To uncover 
neural circuitry variation between clinically diagnosed MDD and healthy control populations, a 
CWAS was performed using the publicly available R software package Connectir (210). In this 
analytic technique, multivariate distance matrix regression (MDMR) is used to identify voxels 
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whose whole-brain connectivity patterns vary significantly between phenotypic variables; in this 
case, the phenotypic variable of interest is a clinical diagnosis (MDD vs healthy controls). 
MDMR itself is a powerful analytic tool that provides advantages over more traditional 
univariate techniques or mass-univariate techniques. Taking a multivariate framework, the 
simultaneous contribution of entire sets of functional connections to clinical diagnosis is 
evaluated reducing the scale of the multiple comparison problem which plagues mass-univariate 
analyses. Given human brain functioning is driven by networks rather than individual regions 
(122) simultaneous analysis of functional connections can reveal network relationships unseen in 
mass-univariate methods.  
The CWAS analysis, as performed by Connectir, was completed in three steps (see (210) 
for more comprehensive methodology description). First, for each participant, the Pearson 
correlation of BOLD fMRI signal between each pair of voxels in the brain was computed, 
resulting in a v x v correlation matrix where v is the number of voxels. Computations were 
restricted to voxels included in all participants’ scans and labeled as gray matter in the prior 
mask provided by FSL (threshold > 0.5). Second, for each voxel, the distance between 
connectivity patterns (i.e., each voxel’s correlation with the rest of the brain) for every possible 
pairings of the participants in the dataset was calculated. The distance measure used was 
√2(1 − 𝑟), where r is the Pearson correlation. The result was an n x n matrix of distances among 
participants for each voxel where n is the number of participants. The third step used MDMR to 
test how well group differences explain the distances between participants obtained in the second 
step. Essentially, MDMR was used to test the differences of connectivity patterns between MDD 
and controls for each voxel. Given MDMR’s regression like framework, movement was 
controlled for using mean FD. The result is a pseudo F-statistic for each voxel where significance 
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was determined using permutation testing. The null distribution was simulated 30,000 times by 
randomly permuting subject labels for the variable of interest and recalculating the pseudo F 
statistic. The p-value for the original pseudo F statistic was determined from this simulation. We 
controlled for multiple comparisons across voxels using Gaussian Random Field theory (voxel 
threshold of Z > 1.65, cluster size threshold p < 0.05). The voxels with the highest significant 
differences in connectivity between MDD and controls were used as the center for post-hoc seed-
based analyses explained below.  
CWAS-Driven Post-Hoc Seed-based Connectivity  
 
 To determine the directionality and specific connections involved in the resultant CWAS 
effect, post-hoc seed-based correlation analysis was performed using 3mm spheres centered on 
voxels deemed significant by CWAS in the comparison across groups (MDD vs. control). Ten 
ROIs were identified in the comparison analysis (Table 3.3 for coordinate information).  In a 
seed-based connectivity analysis, a spatially averaged BOLD time series is obtained from the 
ROI (Figure 3.7) and correlated with the BOLD time series of each voxel across the whole-brain. 
To create a seed-based functional connectivity map, the Pearson correlation coefficient between 
the extracted time series and each voxel in the subject’s preprocessed resting-state scan is 
computed. A seed-based rsFC z-map for each ROI was created by application of a Fisher 
transformation to convert the r-scores to z-scores. This was performed on all resultant ROIs from 
CWAS analysis. 
Seed-Based Connectivity: Data Analysis 
 For comprehensive ROI-specific seed-based functional connectivity z-maps, each 
subject’s ROI-specific connectivity map was entered into a one-sample t-test analysis. Voxels 
were averaged across all subjects and compared to zero. Results were masked at p<0.05-FWE.   
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Two-sample t-tests on each ROI’s seed-based functional connectivity z-map were performed 
across groups (in both directions: MDD>Controls; Controls>MDD). Age was input as a 
covariate along with each subjects’ mean frame displacement value, to control for movement 
across groups. Results were restricted to voxels confined within the masked (p<0.05-FWE) one-
sample t-test result.  
Significance threshold was held at a height of p<0.005 uncorrected; 3dClustSim of AFNI 
(http://afni.nimh.nih.gov) with 1000 Monte Carlo simulations including estimated smoothness 
and the seed-based connectivity map mask’s voxel size was used to compute the critical cluster 
size at p<0.005 (Bonferroni-corrected for number of ROIs in this investigation). All analyses 
were restricted to voxels within those defined by the network-of-interest one-sample t-test 
composed of all 41 subjects’ ROI-specific seed-based functional connectivity z-maps (see table 
below for ROI-specific extent critical cluster size).  
 
Table 3.2: Critical cluster sizes for each ROI-specific seed-based functional connectivity z-
map. Cluster sizes were calculated with 3dClustSim of AFNI and 1000 Monte Carlo Simulations 
for each z-map (as created by one-sample t-test described above). 
 
Region of Interest Critical Cluster Size (> mm
3
) 
Anterior Insula 544 
Left Subgenual Anterior Cingulate  520 
Left Parahippocampus 522 
Mid-Cingulate Cortex 642 
Posterior Cingulate Cortex 509 
Right Parahippocampus 604 
Dorsal-Medial Prefrontal Cortex 486 
Rostral Anterior Cingulate Cortex 474 
Rostral-Dorsal Anterior Cingulate Cortex 544 
Subgenual Anterior Cingulate Cortex 418 
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RESULTS 
Subject Characteristics 
The mean age did not differ significantly between groups (MDD: 22.9 ± 2.7; CTRLS: 21.6 ± 
0.9; t = 1.95; p = 0.06); however, because there was a trend to significant difference, age was still 
input as a covariate for all analyses. Subjects in the depressed group scored significantly higher 
on their baseline PHQ-9 measure (MDD: 18.0 ± 4.5; CTRLS: 1.65 ± 1.7; t = 15.3; p<0.001). 
Although head movement in the scanner was not significantly different across groups (MDD: 
0.24 ± 0.1; CTRLS: 0.21 ± 0.08; t = -1.08; p = 0.28), it was input as a covariate to account for 
any group differences in motion.  
Network Functional Connectivity Group Differences 
Resultant statistical component maps were compared between groups for each network-
of-interest to examine between-group differences in network functional connectivity; however, 
results did not reach statistical significance.  
Within-Network Functional Connectivity Group Differences (Joint ICA Results) 
Due to the null findings from the group ICA, we employed joint ICA to further 
decompose each network in order to gain more sensitivity between groups. For each network, 
resultant statistical component maps were input into the joint ICA analyses and isolated into 
three statistically independent spatiotemporal components. Difference in component expression 
between MDD and controls was examined through a two-sample t-test of subject-specific 
loading parameters associated with each output component. SN (Figure 3.2) results demonstrated 
reduced weight within the bilateral rACC (Figure 3.2C) in MDD compared to healthy controls (p 
= 0.035). Left EN (Figure 3.3): controls demonstrated greater weight in the dlPFC and parietal 
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lobes (Figure 3.4C, p = 0.006). Loading parameters for all other components from each network 
did not differ significantly between groups (p > 0.05).  
Connectome-Wide Analysis 
To demonstrate an alternative method to investigate rsFC between groups which 
addresses some of the group ICA limitations, we employed MDMR-based CWAS to investigate 
whole-brain functional connectivity between depressed and healthy subjects. Fully preprocessed 
resting-state scans for each subject within each group was input into a CWAS analysis, 
functional connectivity for each voxel was computed for each subject. Functional connectivity of 
each voxel was compared with every possible pairing of all other subjects. MDMR produced an 
F-statistic map for each voxel in the whole-brain [(210) for in-depth exploration of 
methodology]: each voxel was tested to determine whether its functional connectivity patterns 
were more similar within-group than between controls and depressed subjects. Voxels with the 
highest statistical significant differences between-groups are shown in yellow (Figure 3.4); the 
coordinates of the voxel with the highest value serve as the center for ROI spheres used in post-
hoc seed-based functional connectivity analysis as they suggest regions with the greatest whole-
brain connectivity differences  between depressed and healthy subjects. Resultant ROIs are listed 
in Table 3.3.  
In order to examine the directionality and specificity of the CWAS results, resultant seed-
based connectivity maps were compared between depressed subjects and controls (Figure 3.5) 
for all ten ROIs listed in Table 3.3. Seed-based connectivity two-sample t-tests were performed 
with age and movement input as covariates to control for any potential differences between 
groups. The results of the analysis are listed in Table 3.4 [and shown (Figure 3.5)], where only 
statistically significant peaks are described.  
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TABLES and FIGURES 
Figure 3.1: Resultant Statistical Network Component Maps. One-sample t-tests composed of 
all 40 subjects’ corresponding network component (DMN, SN, left and right EN, as labeled 
below). Each network is displayed at p<0.05-FWE.  
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Figure 3.2: Salience Network Joint ICA Results. All subjects’ salience network component 
from the group ICA output was input into joint ICA analysis and reduced to three within-
network components [shown in A) and B), each component is displayed in a different color 
(green, cool, and hot)]. C) Shows the independent component with significantly greater loading 
parameters in control subjects than MDD subjects.  
 
 
 
 
 
 
 
 
Figure 3.3: Left Executive Network Joint ICA Results. All subjects’ left executive network 
component from the group ICA output was input into joint ICA analysis and reduced to three 
within-network components [shown in A) and B), each component is shown in a different color 
(green, cool, and hot)]. C) Shows the independent component with significantly greater loading 
parameters in control subjects than MDD subjects [(C; p= 0.006)]. 
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Figure 3.4: Multivariate MDMR CWAS Results. Voxels with significantly different 
functional connectivity pattern between groups (MDD and controls). Voxels in yellow represent 
the highest statistically significant difference between diagnostic groups; voxel coordinates 
served as the center of 3mm radius ROI spheres for post-hoc seed-based functional connectivity 
analysis. Table 3.3 lists ROIs and their respective coordinates.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 
 
Table 3.3: Resultant ROIs from CWAS analysis. All ROIs were created using MarsBar and a 
3mm radius centered on particular coordinate below. 
Anatomical Label Coordinates 
Anterior Insula (aINS) -45, -4, 7 
Subgenual Cingulate -6, 14, -11 
Parahippocampus (Parahipp) -24, -37, -11 
Mid-Cingulate Cortex (MCC) -3, -7, 40 
Posterior Cingulate Cortex (PCC) -9, -55, 13 
Right Parahippocampus (Parahipp) 24, -25, -14 
Dorsal medial Prefrontal Cortex (dmPFC) -6, 50, 34 
Rostral Anterior Cingulate (rACC) -6, 38, -8 
Rostral-dorsal Anterior Cingulate (rdACC) -3, 38, -8 
Subgenual Cingulate Cortex (sgACC) 3, 23, -8 
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Table 3.4: Seed-based Functional Connectivity Results. For each ROI seed-based functional 
connectivity z-map, the table below lists all significant peaks resultant from the two-sample t-test 
analysis between depressed patients and healthy control groups. The directionality of results are 
noted in the row each peak is listed [MDD greater than controls (MDD>); controls greater than 
MDD (CTRL>)]. All peaks pass p<0.005 height (uncorrected) and extent (corrected) threshold. 
See Methods for critical cluster size for each ROI. The following ROIs are not listed because the 
t-test results were null (subgenual anterior cingulate cortex (sgACC) and rostral (rACC). 
Abbreviations are as follows: anterior insula (aINS), parahippocamus (parahipp.), mid-cingulate 
cortex (MCC), posterior-cingulate cortex (PCC), dorsal medial prefrontal cortex (dmPFC), 
rostral-dorsal anterior cingulate (rdACC), somatosensory area (SMA), and medial PFC (mPFC). 
 
 
MDD >
SMA 3, -13, 58 896 3.85
MDD >
CTRL > PCC/Precun. -6, -64, 28 1264 4.01
MDD >
CTRL > rACC 3, 38, 13 1944 4.19
mPFC -6, 62, 1 5968 5.03
dmPFC -18, 38, 49 5968 4.96
cerebellum 30, -76, -35 1656 4.7
CTRL >
MDD >
CTRL > rACC -3, 38, 7 992 3.84
MDD >
CTRL > PCC 6, -49, -5 2320 5.07
MDD >
CTRL >
MDD >
CTRL > PCC -12, -49, 46 848 4.00
Region Coordinates mm
3 z-scoreROI Seed
rdACC
CTRL >
MDD >
Right Parahipp.
dmPFC
sgACC
Left Parahipp.
PCC
MCC
aINS
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Figure 3.5: CWAS Seed-Based Analysis Results: Controls show greater functional 
connectivity. Ten ROIs of interest resulted from the CWAS analysis examining functional 
connectivity differences between MDD and control groups. Each block displays results from a 
single ROI (labelled); showing connectivity greater in healthy controls, unless otherwise 
indicated (MCC-seed). The bottom image shows a one-sample t-test of all subjects’ seed-based 
functional connectivity z-map (at p<0.05-FWE). Top images show two-sample t-test of 
functional connectivity greater in controls, unless otherwise indicated (MCC-seed). Age was 
input as a covariate for all results. Display at p<0.005-uncorrected. All peaks pass height and 
extent significance. See Table 3.4 for peak information. Not shown ROIs: dmPFC, rACC, right 
parahippocampus, and sgACC. 
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DISCUSSION 
 While investigation of whole-brain, rsFC is still an emerging field, its application holds 
weight in uncovering brain regions – in the context of their respective connectivity networks or 
in relation to other regions of interest – involved in the manifestation and maintenance of major 
depressive symptoms. The objective of the present study was to follow-up on the findings 
obtained in Chapter One, from which we were interested whether predictors of treatment 
response were also essential markers of MDD neuopathophysiology, and further examine rsFC 
between a group of depressed individuals and a group of healthy counterparts. By employing two 
disparate methodologies in analyzing rsFC in order to address their respective limitations, we 
provide some information as to the nature of neural connectivity, in the context of intrinsic 
connectivity networks and in regard to more specific brain regions, which differentiates 
depressed from healthy individuals.  
Using group ICA, we did not observe network-based connectivity differences between 
depressed and control subjects. However, upon separating each network into three subnetworks 
with joint ICA, in order to improve sensitivity, we found reduced rACC connectivity within the 
SN, the dlPFC and lateral parietal cortices within the EN of depressed patients compared to 
healthy controls. In a more targeted approach, MDMR-based CWAS identified specific regional 
functional connectivity patterns attributed to each group. Through this methodology, we isolated 
regions of interest possessing more cohesive connectivity maps within each phenotypic group. 
Of interest, depressed patients displayed significantly reduced functional connectivity between 
the PCC and rACC; the left parahippocampus and rACC; sgACC and PCC; and the right 
parahippocampus and PCC. In contrast, depressed subjects demonstrated greater functional 
connectivity between the MCC and dorsomedial prefrontal areas compared to healthy subjects.  
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We did not find significant group effects within the DMN, SN, nor either of the unilateral 
ENs. In contrast to our results, a seminal study observed enhanced functional connectivity 
between the sgACC and thalamus within the DMN in depressed subjects in relation to controls 
(23). It is possible our sample size did not have enough power to detect significant effects or 
differences in ICA model-order contributed to our null findings. While this ICA-based result has 
not been explicitly replicated, increased connectivity in more anterior portions of the DMN, such 
as the mPFC, has been documented in MDD (214). Still, studies utilizing ICA to examine 
network-based functional connectivity in MDD are limited. A recent meta-analysis investigating 
rsFC in MDD in relation to healthy subjects incorporated 36 studies, only eight of which used 
ICA. Generally, ICA reported increased connectivity in anterior regions within the DMN. The 
meta-analysis also reported changes in connectivity between the anterior and posterior regions of 
the network, such as the mPFC or sgACC and PCC, respectively. ICA studies mainly reported an 
anterior and posterior dissociation of the DMN. Interestingly, studies with anterior DMN seed 
regions confirmed this finding, while posterior DMN seed-based studies reported increased 
connectivity between anterior and posterior nodes [reviewed (203)].  
Within-network connectivity of the SN and EN has not been frequently investigated in 
MDD. However, regarding the SN, one ICA-based study reported increased connectivity of the 
ACC with decreased connectivity within the bilateral aINS in depressed patients (207). In the 
same study, the EN was decomposed into three subnetworks due to their use of a high model-
order. Of the subnetworks, the right angular gyrus within the left ventral EN and the postcentral 
gyrus within the right dorsal EN demonstrated increased connectivity in depressed patients. 
Generally, seed-based studies have confirmed decreased connectivity between the major nodes 
of the SN: INS and dACC (215). Although, increased connectivity between the INS and rACC 
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has also been reported (206). A seed-based meta-analysis demonstrated hypoconnectivity of the 
EN as a whole (130). In all, concrete network-based connectivity characteristics of depressed 
subjects warrants more comprehensive examination from larger datasets and standardized 
analytical procedures. Variations in model-orders through an empirical manner will provide 
insight into MDD-associated subnetwork functional connectivity that may also be more sensitive 
to connectivity differences between populations.  
 To honor our objective (investigate whether MDD exhibits particular functional 
connectivity abnormalities within intrinsic large-scale networks), we employed joint ICA to 
further reduce each of the main large-scale networks into statistically independent components 
due to our aforementioned null findings. Within the SN, functional connectivity within the rACC 
had significantly less weight within the SNs of depressed patients in comparison to healthy 
controls. Thus, the region appears to be more cohesive with the rest of the SN in healthy 
controls. The rACC is involved in self-referential, cognitive and affective processes (45); 
decision-making regarding reward attribution (216) and error detection (114); emotional conflict 
(115); and plays a significant role in MDD (44). Across neuro-imaging modalities and 
antidepressant treatments, enhanced pretreatment activity within the region is associated with a 
greater likelihood of successful treatment response. Moreover, we found more cohesive 
functional connectivity within this region and the SN to be a positive predictor of reductions in 
depressive symptoms in response to placebo administration with expectations of antidepressant 
effects as well as in response to antidepressant treatment, although the latter finding was 
observed at a lower statistical threshold. A possible hypothesis may be that MDD patients who 
possess greater integrity or malleability of the region—in the context of SN functional 
connectivity—may be equipped with the neural machinery responsible for or which contributes 
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to recovery from depressive symptoms. This hypothesis holds merit as the region is a central 
intersection between limbic and cognitive brain regions (27, 40) and its abnormal activity 
contributes to the manifestation of MDD (27); however, whether its general activity is 
heightened or diminished is inconclusive. Our findings place the rACC within the context of a 
well-documented, intrinsic connectivity network that may enhance our understanding of the role 
the region and its respective network plays in MDD. Further investigation is warranted in order 
to better detail the specific psychological functions attributed to the rACC within the SN in 
relation to MDD. 
We also found that depressed subjects placed less weight within a component that 
included the majority of the left EN (lateral parietal cortex and dlPFC), further corroborating 
reported diminished connectivity within this network in MDD (130). This muted connectivity 
evinces the practice of rTMS on the network’s main node, the dlPFC (152), as an effective MDD 
treatment for some patients [examination of parietal cortex rTMS as an effective antidepressant 
is inconclusive and limited (217)]. In most cases, stimulation of the left dlPFC produces a 
significant reduction of depressive symptoms, albeit not always full remission (218). Although 
the nature and degree of cognitive deficits in depression still warrants further investigation (219), 
these findings point to disparities in the integrity of the left EN’s functional cohesion between 
depressed and controls: This may contribute to the belief that MDD manifests from inadequate 
regulation by EN-associated cortical, executive regions over heightened limbic activity (27). 
In an effort to address the limitations of ICA-based examination of rsFC (i.e. poor 
sensitivity in uncovering group effects due to model-order), we employed MDMR-based CWAS 
to uncover specific functional connectivity differences between groups. Altogether, in depressed 
patients, we found a pattern of reduced reciprocal functional connectivity between the rACC and 
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PCC; between the PCC and sgACC; PCC and right parahippocampus; and the rACC and left 
parahippocampus. Again, these findings warrant more comprehensive investigation as to their 
psychological and behavioral attributes. Yet, that these regions demonstrate a more cohesive 
interaction (as measured by greater functional connectivity) in healthy subjects, illustrates that 
the quality of their functioning may be essential components in the fruition of healthy cognitive 
and affective states that may be malfunctioning in depressed patients. Furthermore, these regions 
may be potential targets to normalize network dysregulation in MDD. 
As described above in the joint ICA results: the rACC manifests as an integral region in 
the amelioration of MDD symptoms. Consequently, this involves the region in processes such as 
regulating cognition and motivation, emotional decision-making, regulation of primitive, 
emotional responses, and self-referential cognition. Functionally, the region is also encompassed 
within the main anterior node of the DMN (142) and overlaps with the SN (220). The 
parahippocampus is a cortical, paralimbic region involved in processing of external spatial 
orientation, memory functions (221), emotional responses (222), and reward processing (223): it 
plays an important role in MDD. In particular, depression is associated with severe impairments 
in episodic memory (224) as well as a diminished capacity for positive memories (225), which 
contributes to the perpetual negative affective characteristic of the disorder (226). A recent study 
confirmed that MDD is associated with weaker memory for positive material caused by blunted 
activity from the dopaminergic midbrain and the medial temporal lobes, notably, the 
parahippocampus (227). Normally, the presence of rewarding stimuli activate these latter regions 
to enhance episodic memory encoding of positive experiences (228).  
In the framework of the brain’s intrinsic organization, the parahippocampus is 
responsible for mediating the connectivity between the DMN’s main node, the PCC and the 
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hippocampus (229), a region mainly responsible for episodic memory processing and encoding 
(230). The hippocampus and parahippocampus are both subregions of the medial temporal lobe 
(MTL) memory system: another node of the DMN (231). Its central node, the PCC, has been 
shown to increase activity during auto-biographical memory retrieval, future planning, and mind 
wandering (232, 233). Moreover, upregulation of PCC activity has been observed after 
successful antidepressant treatment (24, 28). 
Altogether, our results show that depressed subjects demonstrate diminished connectivity 
between these core DMN regions: the PCC, rACC, and parahippocampus. All of which point to a 
more cohesive DMN functioning within healthy resting connectivity [reviewed (142)]. While 
many in the field speculate that DMN connectivity is excessive in MDD (23, 124, 234), which 
may explain maladaptive ruminative tendencies plaguing depressed individuals (202), evidence 
is still contradictory and inconclusive (125, 235). Here, we show that depressed subjects exhibit 
less functionally connected, or less efficiently communicative DMN nodes. Alternatively, it may 
be the inability to regulate DMN activation that contributes to MDD, as has been demonstrated 
in MDD subjects during emotionally-valenced fMRI tasks (143).   
Enhanced functional connectivity of the DMN was also corroborated by the finding that 
controls also displayed increased connectivity between the PCC and the sgACC, another node of 
the DMN. The sgACC is a central region involved in the regulation of negative mood states and 
extensively implicated in the pathophysiology of MDD (4). Physically, grey matter volume is 
significantly reduced within the sgACC in relation to controls; moreover, the effect is more 
pronounced with more persistent forms of MDD (i.e. chronic, multiple episodes) (236).  
Metabolically, the region is hyperactive during disease states and normalizes upon remission 
induced by antidepressant medications (4) and invasive deep brain stimulation of the region (24). 
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Although our current results cannot decipher the mechanisms associated with increased 
functional connectivity between the PCC and sgACC, it’s possible a more cooperative 
relationship between the two regions may result in better regulation of affective and internal 
states.  
Importantly, the rACC is also functionally connected within the SN. It’s highly possible 
that increased connectivity between the region and the PCC or the parahippocampus 
demonstrates greater inter-network connectivity. Regardless, our results illustrate a heightened or 
more efficient connectivity within major nodes of large-scale networks in healthy subjects. These 
findings may augment the development of targeted interventions which ultimately normalize 
network activity in MDD. There is increasing evidence that psychopathologies, including MDD, 
manifest from an aberrant recruitment of the main networks we’ve investigated: DMN, SN, and 
EN (128). Interactions between these networks guide attentional shifts as well as regulation of 
certain cognitive domains which determine more dominant affective states. Specific to MDD, 
maladaptive rumination associates with DMN dominance over SN and EN activity (129). Our 
results may illustrate where connectivity dysfunction occurs in MDD in the form of network 
hubs. This could be brought into fruition through deep brain stimulation, or even antidepressant 
drugs designed for particular receptors which concentrate within these regions of interest, or 
other region-specific neural characteristics.  
Depressed subjects did show stronger functional connectivity between the MCC and the 
dorsomedial PFC. Prior work did not find MCC connectivity differences between MDD and 
controls (237). With its projections to motor areas, the MCC is associated with response 
selection and skeletomotor function (238, 239). The region is also involved in processing the 
reward value of certain behavioral outcomes (240). As anhedonia is a hallmark attribute of MDD 
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and it’s often seen as an issue in motivational aspects of reward as opposed to consummatory 
lack of pleasure (241), abnormal connectivity of the MCC, with its strong motor connections, 
with the more self-referential, prefrontal regions [also dysregulated in MDD (143)] may 
contribute to this symptom of MDD.  
In all, our results inform our understanding of brain functioning in individuals diagnosed 
with MDD as it compares to currently healthy individuals. Although these findings do not 
attribute functional connectivity abnormalities to certain cognitive or affective processes, they do 
provide an initial framework of neural pathophysiology in MDD which may serve as a 
foundation for further investigation. This would necessitate a substantive sample size: patients 
could be grouped by symptomatology which would better position our understanding of the 
psychological and behavioral processes associated with neural abnormalities. Moreover, it is 
difficult to ascertain whether these abnormalities are an emerging phenotype due to the 
manifestation of depression or whether they are inherent neural abnormalities which give way to 
MDD.  
Moreover, characteristic findings from these two separate approaches to analyze resting-
state functional connectivity data highlight the benefits and deficiencies in each methodology: 
ICA allows for network-based examination of brain functions and thus, all results exist in the 
context of a large-scale network which mimics the network-based framework of actual brain 
functioning (122). However, correct model-order input into an ICA protocol is often nebulous. 
Empirical guidelines for selecting model-order sizes do exist and are based on whether the goal 
is to isolate major large-scale brain networks versus many smaller sub-networks (178). Yet, it 
still remains difficult to determine the optimal model-order for adequate analytical sensitivity, 
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consequently producing false null results. This lack of sensitivity may be why our group ICA 
results were not as significantly robust in comparison to CWAS.  
CWAS, in contrast to ICA, guides analysis by highlighting regions which exhibit the 
greatest disparity in functional connectivity patterns between groups and thus, are prime target 
regions for seed-based functional connectivity (210). However, any significant results exist in 
relation to another region, instead of an entire network, although our results hint at network node 
abnormalities. Altogether, the results from the present study are two-fold: they illustrate 
functional connectivity abnormalities in MDD that instruct our understanding of MDD 
neuropathophysiology as well as the merits of two distinct methodologies for analyzing resting-
state data, an emerging and valuable field within neuroscience research.  
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Chapter Four 
 
Towards Imaging Genetic Markers of Placebo Effects in Major Depression: 
Insights from Prepronociceptin and Placebo Analgesia 
 
 
 High placebo response rates have been observed in Major Depressive Disorder (MDD) 
(47). Yet, investigation into the neurobiology of placebo effects as they relate to MDD has been 
limited (59, 88), despite the therapeutic capability of these effects (242) and their ability to 
confound antidepressant efficacy measurements within randomized clinical trials (RCTs) (243). 
This is a major factor contributing to the discontinuation of antidepressant drug development by 
major pharmaceutical companies (18). In contrast, the field of analgesia, also plagued by high 
placebo response rates in RCTs for chronic pain (244), has made substantial headway in 
uncovering the neurobiological mechanisms involved in placebo responses (52, 53, 57, 156, 
245). From this work, extensive documentation has implicated the endogenous µ-opioid and the 
dopaminergic system in placebo analgesia neurobiology [reviewed (77)]. In further progressing 
these findings, recent evidence has shown the ability of genetic variations within pathways 
related to opioidergic and dopaminergic signaling, as well as endocannabinoid- and serotonergic-
related pathways, to modify placebo effects in depression, as well as in pain and other disorders 
demonstrating inherent placebo responses (54, 81-83). These findings support the possibility of 
implementing genetic screening to better identify placebo responders and in effect, improving 
therapeutic care and RCT efficacy for MDD.   
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Growing evidence supports the notion that an individual’s genetic makeup influences 
their predisposition to respond to placebo treatment [reviewed (80)]. For instance, the gene for 
the monoamine oxidase A enzyme (MAO-A) has been implicated in neuropsychiatric disorders 
such as MDD through its role in metabolizing monoamines, including serotonin and dopamine 
(246). When examining the association between MAO-A genetic variation with antidepressant 
placebo treatment, individuals with the genotype encoding for low-activity of MAO-A, and 
therefore, higher dopaminergic and serotonergic tone, had a significantly higher placebo 
response than those with the highly active MAO-A genotype (87). Relatedly, direct neural 
evidence of dopaminergic neurotransmission has been observed in the placebo effects of 
analgesia (53) and Parkinson’s disease (56). Moreover, genetic variation within the µ-opioid 
receptor gene (OPRM1) modulates placebo-induced dopaminergic neurotransmission within the 
nucleus accumbens, a region central to reward saliency and placebo (53, 55). Across disorders, 
genetic variation within the gene encoding the major dopamine metabolizing enzyme, catechol-
O-methyltransferase (COMT) also modulates placebo effects in patients with irritable bowel 
syndrome (81). In all, with the extensive number of genetic variations showing influence onto 
placebo-related neural pathways, genetic profiling of patients could potentially impact clinical 
trials and therapeutic treatment for a myriad of disorders, including MDD, by improving our 
ability to identify patients with greater susceptibility to placebo treatment.  
A likely candidate genetic predictor of placebo effects in MDD and pain responses is the 
prepronociceptin gene (PNOC). It transcribes prepronociceptin (ppN/OFQ) (247), the 
endogenous precursor protein to the neuropeptide, nociceptin/orphanin FQ (N/OFQ). PpN/OFQ, 
N/OFQ and N/OFQ’s receptor (NOP) (248, 249) form the N/OFQ-NOP system within the opioid 
family (250, 251). This system plays a substantial role in the neurobiology of pain (252), anxiety, 
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stress, and emotional regulation (253), reward circuitry (254), mood (255), and learning (256). 
Animal models of depression have demonstrated stress-induced increases in N/OFQ-NOP 
mRNA expression in limbic regions (257) and strong antidepressant-like behavioral effects in 
response to NOP antagonism (258), comparable with those of common antidepressants such as 
fluoxetine (259). Moreover, elevated plasma levels of N/OFQ have been observed in women 
suffering from post-partum depression (255). In addition, a post-mortem examination found 
significantly decreased expression of N/OFQ in the dorsal anterior cingulate of suicide patients 
(260).  
To examine the capability of PNOC polymorphisms to modulate or predict placebo 
responses, we investigated the association between PNOC variation and placebo-induced µ-
opioid neurotransmission and participant-reported analgesic effects within a well-documented 
pain and placebo challenge (53, 54, 67, 73, 79, 112). The neurobiology of placebo analgesia has 
been extensively investigated [reviewed (67, 77)]; therefore, it provides a stable framework for 
examining the relationship between placebo treatment and novel genetic markers. 
 To further evince the likelihood that PNOC variability may modulate or predict placebo 
responses, the N/OFQ and µ-opioid system have a high homology – the relationship to placebo 
in the latter is supported by a large body of work (52, 57, 73, 82, 156): The PNOC gene shows 
structural similarity to endogenous opioid precursor genes (247) and NOP shares structural and 
functional machinery with the µ-opioid receptor (MOR) (251). There is also evidence of an 
interaction between the two systems: antagonism of N/OFQ can prevent the development of 
morphine tolerance in mice (261) and NOP activation enhances the effects of MOR agonists in 
non-human primates (262).  
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Moreover, the N/OFQ-NOP system is linked to nociception, anxiety and stress; pain and 
analgesia both induce stress-response mechanisms (263) and implicate anxiety (264). Non-
human primate studies have consistently described anti-nociceptive effects of N/OFQ 
administration (133, 265). Across rodent models, administration of N/OFQ produces anxiolytic 
effects (266); while ppN/OFQ knockout mice show excessive anxiogenic behavior and impaired 
stress adaptation (267).  
The present study sought to examine the effect of genetic variations within the PNOC 
gene on placebo-associated µ-opioid neurotransmission. Subjects underwent a sustained pain 
challenge with and without placebo administration (with analgesic expectations) using positron 
emission tomography (PET) with [
11
C] carfentanil, a µ-opioid radiotracer designed to measure µ-
opioid neurotransmission, as previously described (53). Based on previous work in our 
laboratory which demonstrated significant reductions in plasma cortisol levels during a pain 
challenge after placebo administration with analgesic expectations (79), we implemented an 
exploratory analysis on potential gene effects on stress-related measures during the pain and 
placebo challenge: subjects’ plasma cortisol levels were measured during scanning. Furthermore, 
in light of evidence that N/OFQ system is intricately associated with anxiety-like responses in 
animal models (266, 267) and the role of anxiety in placebo responses (15), we sought to explore 
a potential linkage between variation within PNOC and anxiety trait. 
We primarily hypothesize that PNOC variation will modulate placebo-induced µ-opioid 
neurotransmission and associated stress responses; additionally, that genetic variation within this 
gene will be linked to anxiety traits. If confirmed, we will provide evidence of the potential for 
PNOC genetic variation to modulate placebo-related neural pathways, all of which contributes to 
the growing ‘placebome’ (80). Finally, considering the antidepressant properties of the N/OFQ 
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system, this may be particularly applicable to placebo effects in depression, where predictors of 
placebo response are essential to better clinical treatment efficacy and pharmaceutical drug 
development.  
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METHODS 
Subjects 
Forty-nine, non-smoking volunteers [29 females; age: 19 - 40 (mean ± S.D: 26.08 ± 4.9)] 
participated in a pain-stress challenge with and without placebo administration as described 
previously (53). In addition to physical and neurological examinations, participants completed 
the non-patient version of the Structured Clinical Interview for DSM-IV (SCID-IV). Participants 
with current or pervious history of medical, neurological, or psychiatric illnesses (including 
substance abuse or alcohol intake of more than five drinks per week) were excluded. Protocols 
were approved by the University of Michigan Investigational Review Board and the Radioactive 
Drug Research Committee. Written informed consent was obtained from each participant. 
Genotyping 
Single nucleotide polymorphisms (SNPs) of the PNOC gene were genotyped in all 
subjects using the Illumina Golden Gate assay platform (San Diego, California), which employed 
the Addictions Array content of 130 genes (1350 SNPs) and 186 Ancestry Informative Markers 
(AIMs), and has been described elsewhere (268). Manual verification was completed for 
clustering and genotype calling for each locus; loci with call rates <90% were excluded. Using a 
minimum of 160 markers, AIMs scores were calculated through comparison to genotype data 
from the CEPH Diversity panel of similar derivation. Genotyping accuracy was confirmed by 
replicate genotyping of 10% of the total sample with a completion rate of >93% (mean 99.4%, 
median 100%) and replicates showed no errors at this loci. All genotyped subjects were assigned 
to two or, in one case, three groups (Table 4.1). Nine subjects were missing genotyping data for 
SNP rs1563945, so only 40 subjects were reported for that group.  
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Population stratification was evaluated as a potential confounder using European AIM 
scores (since the sample was predominantly Caucasian). To test for population stratification in 
the neuroimaging and personality traits data, we performed Spearman correlations between 
ethnic factor scores and changes in µ-opioid BPND or NEO anxiety scores, respectively. Thus, no 
confounding was present due to ethnic differences. 
Experimental design  
Subjects underwent two PET scanning sessions: one in the absence of (‘pain’ scan) and 
one (‘pain + placebo’ scan) in the presence of placebo administration (Figure 4.1). Each scan 
consisted of a control condition (0.9% isotonic saline, 5-25 minutes after start of scanning) and a 
painful condition (5% hypertonic saline, 45-65 min after start of scanning) delivered in the 
masseter muscle via needle. During the pain condition, a steady state of moderate muscle pain 
was maintained for 20 minutes after radiotracer administration by a computer-controlled delivery 
system through the infusion of medication-grade hypertonic saline solution (5%) into the left 
masseter muscle. Pain intensity was rated every 15 seconds from 0 (no pain) to 100 (most intense 
pain imaginable) using an electronic version of the 100-mm visual analog scale (VAS) and used 
by the computer controller to maintain constant pain in a manner comparable across subjects 
using a target of 40 VAS units, as previously described (269, 270). The same individual infusion 
profiles generated during the pain challenges were used for the studies with placebo 
administration (‘pain + placebo’ condition) (53).  
During the ‘pain + placebo’ condition, subjects were given the following instructions 
before administration of the placebo: “We are studying the effect of a pain relief medication. 
This medication is thought to have analgesic effects through the activation of natural brain 
systems that suppress pain.” The placebo condition consisted of the introduction of 1mL of 0.9% 
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isotonic saline into one of the intravenous ports every four minutes, with the volunteer being 
made aware of its occurrence. The placebo was introduced starting two minutes before the pain 
challenge and each injection lasted 15 seconds: subjects were aware that the study drug was to be 
administered because they were alerted by a computer-generated human voice recording, 
followed by a second-by-second count of the infusion timing (15 seconds). The VAS was 
administered as during the pain condition.  
At the immediate completion of each challenge, ‘pain’ and ‘pain + placebo,’ subjects 
provided a qualitative measure of the experience by completing the McGill Pain Questionnaire 
(MPQ) (271), including an overall assessment of affect, sensory, intensity and unpleasantness 
aspects of pain. These measures along with the VAS scale scores served as a measure for 
psychophysical placebo response. Differences in values within these measures between 
conditions (‘pain’ - ‘pain + placebo’) were calculated to measure reported analgesic effects. 
Larger positive numbers on this calculated measure reflect greater reported placebo analgesic 
responses. Levels of expectancy and effectiveness of placebo were rated before and after the 
placebo administration, respectively, with the questions: a) expectancy: ‘From 0 to 100 how 
effective do you think the treatment will be?’ and b) effectiveness: ‘From 0 to 100 how effective 
do you think the treatment was?’ The internal affective state of the volunteers was rated with the 
Positive and Negative Affectivity Scale (PANAS) (272) and the Profile of Mood States (POMS) 
before and after the scanning session. The composite Total Mood Disturbance score (TMD) was 
used to evaluate the transient changes in negative mood (POMS-TMD) (273). 
PET Data Acquisition and Preprocessing 
Each subject underwent two 90-minute PET scans with [
11
C] carfentanil, a µ-opioid 
receptor agonist radiotracer (274). For each scan, 15 ± 1 mCi (mean ± SD) of [
11
C] carfentanil 
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was administered via an intravenous (antecubital) line. Radiotracer synthesis and image 
acquisition, coregistration, and reconstruction protocols were identical to those used in previous 
publications (53).  
Three receptor-related measures were calculated: 1) µ-opioid BPND during the control 
condition (pain anticipation); 2) µ-opioid BPND during the pain challenge and 3) µ-opioid BPND 
during the ‘pain + placebo’ challenge (Figure 4.1). Activation of the µ-opioid system during 
‘pain’ and ‘pain + placebo’ administration was assessed by calculating the µ-opioid BPND 
difference between control and pain conditions; and between ‘pain’ and ‘pain + placebo’ 
conditions, respectively; activation of the µ-opioid system during placebo administration with 
only the expectation of pain was assessed by µ-opioid BPND difference between the ‘pain + 
placebo’ and ‘placebo pain anticipation’ scan times. Reductions in the in vivo availability of µ-
opioid receptors (i.e., binding potential [BP]) after an acute challenge are thought to reflect µ-
opioid activation through competition between radiotracer and endogenous ligand for the 
receptor sites (275). 
Statistical Analyses 
A voxel-by-voxel mixed model of variance analysis was performed using SPM8 
(Wellcome Department of Cognitive Neurology, University College, London) and Matlab 
software (MathWorks, Natick, Massachusetts). No global normalization was applied to the data, 
and therefore the calculations are based on absolute BPND values. A cortical mask which 
excluded the cerebellum but included regions with specific µ-opioid receptor binding potential 
(BPND> 0.1) was used for the PET data.  
ANCOVA models were performed using genotypes for each independent SNP as the 
between-subject factor and four within-subject conditions (pain; pain + placebo condition; and 
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their corresponding control conditions); sex and scan order were input as covariates. The 
threshold for significance for neuroimaging analysis was set at peak-level of p<0.05 family-wise-
error corrected to account for multiple comparisons of the voxel-based analysis. The stringency 
of this threshold was determined to account for independent SNP comparisons. These data were 
extracted for quantification of regional changes in BPND, plotting, examination of potential 
outliers and further statistical analyses using SPSS statistical Software (version 20.0; SPSS, Inc. 
Chicago, Illinois). Data are expressed as the mean  1 S.D., unless otherwise indicated.  
Cortisol Collection and Analysis 
Samples of blood were collected at a 10 minute interim over the course of each 90 minute 
scan. Only 34 subjects had complete blood collection that could be used for analysis. Cortisol 
was assayed using the automated Immulite 1000 chemiluminescent cortisol assay (Siemens 
Medical Solutions Diagnostic Division) with intra- and inter-assay variability of <5% and 7%–
8%, respectively. Each pair of scans: ‘pain with placebo’ and ‘pain without placebo’ was 
conducted at the same time of day (starting at 8.30 a.m. or at 1.30 p.m.). Differences in plasma 
cortisol level between the ‘pain + placebo’ condition and the ‘pain’ condition were plotted 
(Figure 4.4: ‘pain + placebo’ – ‘pain’) for each 10 minute period between 0 and 90 minutes. For 
a sensitive measure of placebo-induced changes in cortisol plasma levels, area under the curve 
(AUC) was calculated with respect to increase (AUCI) from placebo administration onset (time 
point 40-minute), as comprehensively described elsewhere (276). Briefly, for each subject, total 
AUC was calculated between scan time point 40- and 50-minutes; AUC with respect to the 
baseline (AUCB) of this interim (the 40-minute time point) was calculated and subtracted from 
the total AUC values to compute AUCI (AUCI = total AUC – AUCB). Therefore, decreases in 
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cortisol plasma levels after placebo administration are reflected by negative values within this 
measure. 
Significant differences in placebo-induced changes in cortisol plasma levels between 
genotypes were examined via two-sample t-test using SPSS (SPSS for Macintosh, version 17; 
SPSS, Chicago, Illinois) with baseline cortisol plasma levels input as a covariate. Data are 
expressed as the mean ± 1 SD, unless indicated otherwise. 
Trait Anxiety measures  
We assessed subject trait anxiety using the anxiety facet of the neuroticism domain from 
the Revised NEO- Personality Inventory (277) and the ‘pain’ and ‘pain + placebo’ state and 
overall anxiety measures were also evaluated with the State Trait Anxiety Inventory (STAI) 
(278).  
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RESULTS 
SNP-based analysis  
Forty-nine healthy volunteers were genotyped for the seven PNOC SNPs on the array: 
rs2722897, rs1563945, rs7825480, rs2614095, rs351776, rs351784, rs4732850 (see Table 4.1 for 
allele distribution and demographic information). Linkage disequilibrium occurred between 
rs1563945 and rs7825480; and between rs2614095, rs351776, rs351784, and rs4732850 (Figure 
4.2). Based on these linkage disequilibrium results, three independent analyses were considered 
for statistical purposes and thus, significance for behavioral data was established at a p<0.017 
after Bonferroni correction. Still, to avoid the existence of multiple groups within each 
haplotype, independent SNP-based analyses were performed on the neuroimaging and behavioral 
data for each of the seven PNOC SNPs on the array (with neuroimaging data FWE-corrected for 
multiple comparisons). 
PNOC rs1563945 effect on placebo-induced ∆ in µ-opioid BPND  
To investigate the effect of genetic variation within the PNOC gene with our available 
sample size, we performed seven SNP-based analyses on pain- and placebo-induced opioid 
activation maps. Among the seven SNPs in the Addiction Array, only rs1563945 showed a 
significant effect on placebo-, but not pain-induced opioid release. None of the other six PNOC 
SNPs had a significant effect on pain- or placebo-induced opioid activation; this included 
rs7825480 which is in linkage disequilibrium with rs1563945. Compared to their genetic 
counterparts, rs7825480 ‘G’ carriers did demonstrate a placebo-induced increase in µ-opioid 
activation in the thalamus although at a lower statistical threshold [(MNI coordinates x, y, z, 
cluster size mm
3
, Z-score, for all regions p<0.05 FWE-corr): 14, -5, 2, Z = 4.09; p = 0.3-FWE-
corr].  
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Specifically, PNOC rs1563945 ‘A/A’ homozygotes, compared to ‘C’ carriers, showed 
placebo-induced increases in µ-opioid activation in the following regions [MNI coordinates 
x,y,z, cluster size mm
3
, Z score, for all regions p<0.05 FWE-corr (Figure 4.3)]: left rostral 
anterior cingulate cortex (rACC); -13, 55, 16; 184 mm
3
; Z = 4.82; p = 0.019-FWE;  mid-
cingulate cortex (MCC); -5, -11, 38; 128 mm
3
; Z = 4.93; p= 0.013-FWE; right caudate; 23, 19, 
11; 144 mm
3
; Z = 4.84; p= 0.018-FWE; left posterior insula (pINS); -38, -29, 20; 144 mm
3
;  Z = 
4.7; p= 0.03-FWE; and right parietal lobule (PL); 58, -55, 19; 72 mm
3
; Z = 4.93; p=0.013-FWE. 
A gene effect on placebo-induced µ-opioid activation was also observed at a lower threshold 
(p<0.001 uncorrected) in the right parahippocampus (16, -32, -8; 9,408 mm
3
; Z= 4.52; p<0.001) 
and left posterior thalamus (-17, -30, 1; 9,032 mm
3
; Z = 4.50; p<0.001). No significant effects 
were found in the opposite direction (‘C’ carriers > ‘A/A’).  
During placebo administration with only expectation of imminent pain, an effect of 
PNOC rs1563945 (‘A/A’ > ‘C’ carriers) on µ-opioid activation in the left rACC (-12, 43, 21; 
17,624 mm
3
; Z= 4.52; p<0.001-uncorr.) and the right caudate (22, 23, 5; 10,688 mm
3
; Z= 4.33; 
p<0.001-uncorr.) was also observed at a lower threshold. There was no significant effect on pain-
induced ∆ in µ-opioid BPND.  
A quantification of genetic group differences in placebo-induced ∆ in µ-opioid BPND is 
shown in Figure 4.3B; the same pattern was observed across all regions mentioned above.  
PNOC rs1563945 effect on placebo-induced ∆ in µ-opioid BPND and psychophysical placebo 
measures and affective states 
In regions relevant to sensory and affective regulation of pain and placebo responses: 
placebo-induced regional activation of µ-opioid neurotransmission under PNOC rs1563945 
influence was significantly correlated with psychophysical responses to placebo, as measured by 
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changes in MPQ Total, Sensory, Affect and Pain Intensity score after placebo administration 
(Figure 4.3A; see Table 4.2 for comprehensive results; PANAS and POMS were not included for 
clarity due to minimal significant findings). Placebo-induced changes in psychophysical placebo 
measures were calculated by ‘pain’ – ‘pain + placebo’ scores. Therefore, more positive values 
indicate greater reported placebo response (reduction in self-reported pain experience with 
placebo). In correlation results between opioid and psychophysical measures, positive 
correlations indicate greater placebo induced µ-opioid activation associates with greater changes 
(i.e. greater placebo response), in reported pain ratings.  
PNOC rs1563945 effect on ∆ in pain and affect ratings after pain and after placebo 
administration  
We found no effect of rs1563945 on reported pain experiences: as measured by the MPQ, 
average VAS scores, volume of hypertonic saline to achieve average target pain ratings or the 
ratio between VAS ratings and volume infused to achieve target ratings. Instead, we observed a 
significant effect of PNOC rs1563945 (‘A/A’ > ’C’ carriers) on behavioral placebo response as 
measured by the MPQ Intensity ratings (‘pain’ – ‘pain + placebo’): (AA: 10.2 ± 14.9; C Carriers: 
- 4.1 ± 16.7; F = 8.0, p = 0.007); the same was observed with average VAS ratings in the first ten 
minutes: (AA: 1.1 ± 1.4; C Carriers: .26 ± 1.1; F = 4.3, p = 0.045) at a trend level. Similarly, at a 
trend level, ‘A/A’ homozygotes self-reported lower expectations of placebo effectiveness (AA: 
40.2 ± 26.4, C Carriers: 58.4 ± 24.9; F = 4.6, p = 0.039); however, not for observed placebo 
effectiveness (AA: 83.63 ± 24.8, C Carriers: 81.8 ± 27.8; F = 0.018, p = 0.8). A trending gene 
effect was also observed on placebo-induced changes in pain ratings within MPQ Total (AA: 4 ± 
8.7, C Carriers: -0.75 ± 8.6; F = 0.64, p = 0.09), Sensory (AA: 2.37 ± 5.7, C Carriers: - 1.0 ± 5.7; 
F = 0.036, p = 0.078) and Affect (AA: 1.45 ± 2.8, C Carriers: - 0.12 ± 2.4; F = 0.38, p = 0.072). 
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Of the other six PNOC SNPs, only rs351776 showed a significant effect on behavioral 
placebo as measured by MPQ Intensity (AA: 10 ± 21.4; AC: -3 ± 11.7; CC: 11.7 ± 8.3; F = 5.2, p 
= 0.009), Average VAS (0-10 minutes) (AA: 1.3 ± 1.4; AC: .06 ± 1.3; CC: .97 ± .9; F = 4.8, p = 
0.013), and at a trend level, with MPQ Affect (AA: 1.07 ± 3.5; AC: -0.24 ± 1.9; CC: 2.8 ± 2.9; F 
= 4.3, p = 0.019). It also had a significant effect on pain ratings: MPQ Total (AA: 17.9 ± 8.3; 
AC: 21.8 ± 11.3; CC: 31.6 ± 10.9, F = 5.2, p = 0.009) and MPQ Sensory (AA: 11.2 ± 5.8; AC: 
13.7 ± 6.4; CC: 21 ± 4.1, F = 8.0. p = 0.001).  
None of the PNOC SNPs had a significant effect on pain- or placebo-induced changes in 
positive and negative affect as measured with the PANAS and POMS.  
PNOC rs1563945 effects on pain and placebo-induced changes in cortisol plasma levels 
Based on previous findings demonstrating placebo-induced reductions in cortisol levels 
(79) and our current findings showing an effect of PNOC rs1563945 on placebo-induced µ-
opioid activation, we examined the effect of rs1563945 on plasma cortisol level changes after 
placebo administration. There was a significant gene effect on placebo-induced stress responses 
as measured through cortisol plasma levels. Compared to ‘C’ carriers, ‘A/A’ homozygotes 
showed a decrease in cortisol plasma levels in response to placebo administration (Figure 4.4). 
AUCI analysis of cortisol levels in response to placebo administration (minute 40 to 50 of scan 
time) resulted in a significant difference between genotypes (AA: -13.6 ± 32; C carriers: 4.6 ± 
19; F = 4.7, p = 0.039). Here, negative values illustrate reduction in cortisol at the onset of 
placebo administration. This stress-response measure was also significantly, negatively 
correlated with placebo-induced ∆ in µ-opioid BPND in the rACC and caudate (Table 4.2; Figure 
4.4); therefore, greater placebo-induced opioid activation is associated with greater decreases in 
plasma cortisol levels.  
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PNOC SNP effects on STAI and NEO Anxiety Measures 
We found that placebo-induced Δ in µ-opioid BPND in the rACC was significantly 
negatively correlated with anxiety [rACC: STAI r = - 0.43, p = 0.005; NEO r = - 0.37, p = 0.02 
(Table 4.2)]. Therefore, we explored a potential link between PNOC and anxiety trait, however 
the size of our sample limits our ability to form substantiated generalizations about PNOC SNP 
effects on personality traits. Still, from an exploratory interest, we find that PNOC rs1563945 
showed a trending effect on trait anxiety as measured by the Anxiety NEO: ‘A/A’ homozygotes 
showed lower levels of anxiety trait, compared to ‘C’ carriers. However, rs7825480 did not show 
an effect on trait anxiety. Among all the other PNOC SNPs, rs2614095 and rs4732850, which are 
in linkage disequilibrium, showed a significant effect on trait anxiety score as measured by the 
STAI. PNOC rs351776 and rs351784 (Figure 4.2), also in linkage disequilibrium with rs2614095 
and rs4732850, showed an effect on STAI score, although at a trend level. The means and 
significance values are shown in Table 4.3 along with SNP effects on Anxiety NEO.  
State anxiety measures were taken during ‘pain with’ and ‘pain without’ placebo 
administration: again, only rs1563945 showed a gene effect on state STAI during pain (AA: 30.4 
± 4.9; CC: 39.7 ± 5.6; F = 13.8, p = 0.002) and placebo-induced reductions in state anxiety (AA: 
-3.6 ± 5.9; C Carriers: 1.44 ± 4.6; F = 3.9, p = 0.06) at a trend level. However, STAI state 
measures were only available for 18 subjects (9 ‘A/A’).  
100 
 
Figure 4.1: Experimental Design All subjects underwent two 90 minute PET scans after [
11
C] 
carfentanil injection. Each scan consisted of a control condition (0.9% isotonic saline, 5-25 
minutes after start of scanning) and a painful condition (5% hypertonic saline, 45-65 min after 
start of scanning) delivered in the masseter muscle via needle. Pain intensity was rated every 15 
seconds from 0 (no pain) to 100 (most intense pain imaginable) using VAS; pain maintained at a 
level of 40 VAS units via computer-controlled infusion. Placebo was introduced with 1 ml of 
0.9% isotonic saline solution every four minutes, starting two minutes prior to pain anticipation 
and pain challenges.  
 
 
 
 
 
 
 
 
Figure 4.2: Linkage Disequilibrium of the Seven PNOC SNPs included in the analysis. The 
haplotypes match those identified in the HapMap Project.  
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Table 4.1: Demographic and Hardy-Weinberg Equilibrium Data for PNOC SNPs 
SNP-based comparison of age and European AIM demographics; H-W results. Sex (M/F = 
20/29) and ethnicity (Caucasian/Total = 38/49) distribution were identical for all SNPs (except 
rs1563945: 18M/22F; 29 Caucasian/Total) and thus, were excluded from table data. There were 
no significant differences with respect to sex between genotype groups within each SNP group. 
(*p<0.05, **p<0.01, ***p<0.001). 
 
 
 
  Demographics Hardy-Weinberg  
PNOC SNP Age 
European 
AIM 
Chi² p value 
rs2722897     .27 .6 
GG (34) 26.2 ± 4.8 .68 ± .4     
A Carriers (15) 24.2 ± 4.7 .64 ± .4     
rs1563945      < .001 .98 
AA (24) 25.7 ± 4.3 .7 ± .4     
C Carriers (16) 26.6 ± 5.5 .5  ± .4     
rs7825480     .39 .5 
AA (32) 25.9 ± 4.3 .68 ± .4     
G Carriers (17) 26.4 ± 6 .64 ± .4     
rs2614095     .36 .55 
GG (22) 26. 2 ± 6 .54 ± .4*     
A Carriers (27) 25.9 ± 4 .77 ± .3*     
rs351776     .06 .8 
AA (15) 25.4 ± 5 .53 ± .4     
AC (25) 26.2 ± 5 .68 ± .4     
CC  (9) 26.7 ± 3 .84 ± .2     
rs351784     3.5 .06 
GG (29) 26.6 ± 5.6 .8 ± .3**     
C Carriers (20) 25.3 ± 3.5 .4 ± .4 **     
rs4732850     .03 .86 
GG (37) 26.4 ± 5 .72 ± .4     
A Carriers (12) 25.6 ± 4 .49 ± .4     
 
Note: 
All analyses of rs2614095 and rs351784
 
were completed with European AIM as a covariate
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Table 4.2: Association between PNOC rs1563945 placebo-induced Δ in µ-opioid BPND with 
psychophysical placebo measures, anxiety, and plasma cortisol levels. µ-opioid activation in 
regions under PNOC rs1563945 influence was correlated with behavioral placebo measures: 
MPQ Total, Affect, Sensory, Unpleasantness, Intensity, and Average VAS (positive correlations 
signify greater opioid activation relates to greater reported placebo analgesic effects); trait 
anxiety measures: STAI and NEO Anxiety; and plasma cortisol levels. Cortisol levels were 
measured as the difference between cortisol plasma levels at time points: 40 minutes to 50 
minutes at ‘placebo + pain’ from ‘pain’ condition.  (**p<0.017, ***p<0.001).  
 
 
 
  
rACC MCC Caudate Posterior 
Insula 
Parietal 
Lobule   
  r r r r r 
Placebo-Induced Δ in Pain Rating     
Total McGill .4** .02 .4** .3 .3 
McGill Affect .4 .1 .4** .3 .4** 
McGill Sensory .4** .1 .4 .3 .3 
McGill  Pain 
Unpleasantness 
.2 .1 .2 .1 .3 
McGill Pain Intensity  .3 .2 .3 .2 .3 
Avg VAS (0 - 20 min.) .3 .1 .4** .2 .35 
Avg VAS (0 to 10 min.) .3 .2 .4 .3 .3 
Trait Anxiety Measure 
    
STAI Trait -.4** -.2 -.05 -.4 -.2 
Anxiety NEO -.4 -.3 -.1 -.3 -.2 
Placebo-induced Δ in Cortisol Plasma Level 
  
AUC 40 to 50 min. -.4* .05 -.7*** -.3 -.5** 
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Table 4.3: PNOC SNPs and Trait Anxiety 
All PNOC SNP effects on STAI Trait and NEO Anxiety scores. Total subject number for each 
genotype given accordingly. (*p<0.017, **p<0.001).
 
 
 
 
 
 
 
 
 
 
 
 
 
  Trait Anxiety Measure 
PNOC SNP    (N) 
STAI Trait Anxiety NEO 
Mean F Sig. N Mean F Sig. 
rs2722897               
GG (34) 37.7 ± 10 
4.5 .04 
33 14.6 ± 5.9 
.3 .6 
A Carriers (15) 31.6 ± 5.5 15 13.7 ± 5 
rs1563945               
AA (24) 33.1 ± 7.4 
1.28 .26 
24 12.75 ± 4.3 
3.8 .057 
C Carriers (16) 36.3 ± 10.2 15 15.9 ± 5.7 
rs7825480               
AA (32) 35.6 ± 9 
0.053 .8 
32 13.7 ± 5 
.9 .35 
G Carriers (17) 36.3 ± 10 16 15.4 ± 6.6 
rs2614095               
GG (22) 32 ± 7  
7.1 .01* 
21 12.9 ± 5.7 
3.4 .072 
A Carriers (27) 38.9 ± 10 27 15.4 ± 5.5 
rs351776               
AA (15) 31.6 ± 5 
4 .025 
15 11.4 ± 4.6 
3 .057 AC (25) 36 ± 9.7 24 15.7 ± 5.8 
CC  (9) 42.3 ± 11.5 9 15.4 ± 5.4 
rs351784               
GG (29) 38.4 ± 10 
6.6 .013* 
28 15.1 ± 6 
3.1 .083 
C Carriers (20) 32.1 ± 7 20 13.2 ± 5 
rs4732850               
GG (37) 37.9 ± 9.7* 
8 .007* 
36 15 ± 6 
1.5 .22 
A Carriers (12) 29.5 ± 5* 12 12.6 ± 4 
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Z-score 
rACC 
pINS 
caudate 
Figure 4.3: PNOC rs1563945 effect on placebo-induced µ-opioid system activation 
A) Association between placebo-induced Δ in µ-opioid BPND with placebo response 
(measured by Total MPQ score: pain – ‘pain + placebo’ conditions (r = 0.43; p = 0.004).  
B) Quantification of placebo-induced Δ in µ-opioid BPND in the rACC (pain – ‘pain + 
placebo’) conditions in each rs1563945 genetic group. An identical pattern was observed 
across all significant regions.  
C) Regions of greater µ-opioid release during placebo administration in A/A homozygotes 
compared to C carriers. Image display at p<0.005 uncorrected.  
 
                           
       
A 
C 
B 
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Figure 4.4: PNOC rs1563945 effect on placebo-induced Δ cortisol plasma levels  
Plotted: A. Placebo-induced changes in cortisol plasma levels (µg/dl) [plotted: ‘pain + placebo’ – 
‘pain’] for each genotype group (solid: ‘A/A’ homozygotes; dotted: ‘C’ carriers). Placebo 
administration began at minute 42. B. Quantification of changes in cortisol plasma levels in 
response to placebo administration (40 to 50 minute time point). Negative values demonstrate 
reductions in cortisol plasma levels in response to placebo (‘pain + placebo’ – ‘pain’). C. 
Association between placebo-induced reductions in µ-opioid BPND (‘pain’ –‘pain + placebo’) in 
the caudate with changes in cortisol plasma levels (‘pain’ - ‘pain + placebo’) conditions during 
the timeframe of placebo administration (50 minutes – 40 minutes after the start of scan time;  r 
= 0.6; p<0.001). Here, more positive values demonstrate greater placebo-induced reductions in 
cortisol levels at the 50 minute time point versus at 40 minutes.  
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DISCUSSION 
The present study examined the effects of PNOC polymorphisms on placebo-induced µ-
opioid neurotransmission and plasma cortisol levels. Among the seven PNOC SNPs examined, 
rs1563945 had a significant effect on µ-opioid activation in response to placebo administration in 
several brain regions: the rACC, MCC, pINS and caudate. PNOC rs1563945 ‘A/A’ homozygotes 
showed greater placebo-induced µ-opioid activation and self-reported psychophysical placebo 
responses, yet lower expectations of placebo effectiveness compared to their ‘C’ carrier 
counterparts; an identical gene effect, albeit at a lower statistical threshold, was also observed 
within the rACC during placebo administration with expectations of pain, but prior to actual 
infusion. A significant difference between genotypes in their stress response was also apparent 
through contrasting patterns of placebo-related changes in plasma cortisol levels: ‘C’ carriers 
demonstrated an increase in plasma cortisol levels, whereas cortisol levels of ‘A/A’ 
homozygote’s declined. In connection, placebo-induced cortisol fluctuations were significantly 
associated with placebo-induced µ-opioid system activation in the rACC and caudate. Placebo-
induced µ-opioid activation within these same regions was also significantly, negatively 
correlated with anxiety trait. Finally, an association between the PNOC gene and trait anxiety 
was observed within multiple SNPs of the same haplotype (rs2614095 and rs4732850), while 
rs1563945 demonstrated a weaker relationship. 
Although our investigation would be aided by a NOP radiotracer [which is currently 
unavailable, but in development (279)], we provide some insight about the involvement of this 
opiate member in placebo analgesia through the examination of PNOC gene effects on μ-opioid 
activation in response to placebo administration. The μ-opioid system’s key role in establishing 
placebo analgesic effects has been well-documented (53, 57, 73). Specifically, we found that 
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PNOC rs1563945 ‘A/A’ homozygotes showed substantially greater placebo-induced μ-opioid 
neurotransmission than their complementary group of ‘C’ carriers within the follow regions: the 
rACC, caudate, pINS, MCC and parietal lobule. In actuality and in contrast to their genetic 
counterparts, ‘C’ carriers displayed increases in µ-opioid BPND within these regions, signifying a 
reduction in opioid neurotransmission. While rs1563945 is a non-functional SNP, this disparity 
between genotypes highlights PNOC’s influence, and by deduction, its neuropeptide products 
and associated receptors, on placebo-associated neural mechanisms. Of further interest, 
mounting evidence has described activity, including μ-opioid neurotransmission, within the 
rACC as an integral region in the formation of placebo analgesia (57, 72, 73, 113, 156). 
Moreover, involvement of the caudate, pINS, and MCC have also been documented in placebo 
neurobiology in the context of pain and major depression (53, 280). Our results suggest that 
ppN/OFQ and its family of products and receptors possess a level of influence on molecular 
mechanisms within placebo-associated brain regions.  
We also observed that μ-opioid activation after placebo administration was significantly, 
negatively correlated with participants’ trait anxiety levels. More specifically, we found that 
PNOC rs1563945 ‘A/A’ homozygotes, in addition to greater μ-opioid release in response to 
placebo, demonstrated lower levels of anxiety, albeit at trend levels. However, we found a 
significant gene effect of two other SNPs: rs2614095 and rs4732850 [both members of another 
haplotype (Figure 4.2)] on trait anxiety. While it is difficult to make substantial conclusions from 
our results due to our subject sample size, these findings hint at a potential relationship between 
the human N/OFQ-NOP system and anxiety as has been found in animal models: anxiolytic 
effects have been observed with low doses of N/OFQ administration (253) and non-peptide NOP 
agonists (266, 281). Yet, opposing findings have also been described with intracerebroventricular 
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N/OFQ administration (282). Importantly, our results suggest a contributory role of the N/OFQ-
NOP system in modulating μ-opioid-based mechanisms associated with placebo analgesia and 
anxiety. Anxiety appears to be an important factor in placebo responses: research investigating 
personality predictors of placebo analgesia found low trait anxiety levels to predict better 
placebo responses (283) and reductions in anxiety are involved in the formation of placebo 
responses (284). Moreover, a functional MRI study found an association between placebo 
responses and reduced activation within anxiety-related brain regions (285).  
Regarding stress responses to placebo analgesic administration, we observed that ‘A/A’ 
homozygotes demonstrated a placebo-induced drop in plasma cortisol levels. This pattern was 
significantly different from their ‘C’ carrier counterparts who showed a placebo-induced 
increase. Furthermore, plasma cortisol reductions in response to placebo administration were 
significantly associated with placebo-induced µ-opioid neurotransmission, confirming previous 
findings (79). Previous experimentation has observed that µ-opioid receptors are involved in the 
neurobiology of stress (74), stress-induced analgesia (286), and placebo analgesia (73) which is a 
stress-related mechanism (67). However, the direct relation between cortisol [the output of the 
stress response regulator, the hypothalamic-pituitary-adrenal axis (HPA) (287)] and molecular 
mechanisms of placebo analgesia is limited (79) and often this link has been disputed (288, 289). 
Here, we find significantly different patterns of placebo-induced plasma cortisol in placebo 
responders (‘A/A’ homozygotes) and non-responders (‘C’ carriers). These results strengthen 
existing evidence that placebo analgesia manifests through stress reduction (52) by opioid 
modulation of the HPA axis (290, 291). On the other hand, nocebo, or increases in pain, 
responses are related to increases in stress and anxiety: a study found benzodiazepine 
administration, a common anti-anxiety agent, to block nocebo-induced HPA hyperactivity and 
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hyperalgesia (292). Similarly, this pattern was replicated here: ‘A/A’ homozygotes – generally 
the responders – along with placebo-induced reductions in plasma cortisol levels, demonstrated 
placebo-induced anxiety relief, whereas their genetic counterparts – the non-responders – 
showed a placebo-induced increase in cortisol and anxiety. The anxiety findings were observed 
at lower statistical threshold, however this could be due to a diminished sample size for state 
anxiety measures. 
 Animal studies have also revealed ppN/OFQ and N/OFQ to have a large, yet 
complicated role in stress regulation and anxiety (132): in comparison to wild-type mice, 
ppN/OFQ knockout mice display an anxiogenic phenotype in reaction to environmentally-
induced stress (293). The same effects are observed in N/OFQ-specific knockouts (267). 
Furthermore, NOP agonists induce anxiolytic behavior across rodent species (266, 294). 
However, contradictory evidence is also extant: N/OFQ administration increased anxiogenic 
behavior in rats (295), confirmed by induced anxiolytic behavior after NOP antagonism (296). 
Of interest, anxiety-related effects of N/OFQ appear to stem from an interaction with 
corticotrophin release factor (CRF), a major modulator of stress responses (297): N/OFQ 
infusion prior to CRF blocked the anxiogenic effects of CRF in rats (298). While the exact 
pathways and definitive effects of the N/OFQ-NOP system in relation to anxiety and stress are 
still elusive, the existence of its involvement in anxiety- and stress-associated mechanisms is 
indisputable (299). Our findings suggest a role in humans as well, which requires further and 
extensive probing.   
Importantly, our results add to the growing literature understanding the genetic 
underpinnings of placebo effects: the placebome (80). To our knowledge, this is the first study to 
unearth a connection between genetic polymorphisms within the N/OFQ opiate family and 
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placebo, stress-related mechanisms, and anxiety in humans. These mechanisms are intertwined 
as anxiogenic behavior is elicited in response to stressful (threatening) situations (300), such as 
pro-nociceptive stimuli. Moreover, placebo analgesia is viewed as a mechanism utilized in 
stressful situations to combat perceived stress (i.e. a pain challenge) and is associated with 
reductions in anxiety (301). It is difficult to speculate on the molecular pathways contributing to 
our results. However, the implication of N/OFQ opiate family in placebo, anxiety and stress is 
sufficient to address the need for further investigation. This may also provide insight into the 
functionality between and within placebo, anxiety and stress; ultimately, contributing to a more 
comprehensive understanding of placebo-related pathways and the nature of their genetic 
influences.  
In particular, examination of PNOC polymorphisms has provided insight into the 
physiological and psychological patterns associated with placebo responses: individuals of a 
specific genotype (rs1563945 A/A) exhibited greater µ-opioid neurotransmission in response to 
placebo and self-reported analgesic effects, which was accompanied by reductions in plasma 
cortisol levels, and lower expectations of placebo effectiveness. While the complementary 
genotype demonstrated a lack of reported analgesic effects and diminished placebo-induced µ-
opioid neurotransmission. This was accompanied by increased plasma cortisol levels and 
expectations of placebo effectiveness. Moreover, insight can be gained by acquiring additional 
evidence to prior hypotheses: For instance, a recent study in our laboratory posited the 
discrepancy between expected and observed outcomes in regard to placebo effectiveness as a 
cognitive mechanism underlying placebo responses (71); here, there were no significant 
differences between observed placebo effectiveness across genotypes, yet rs1563945 ‘A/A’ 
homozygotes had lower expectations of placebo analgesic efficacy.  
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Further investigation into the genetic effects of PNOC polymorphisms on placebo-
associated pathways is warranted, especially in MDD. Our findings support the potential of this 
gene to mark individuals likely to respond to placebo treatment. This is particularly relevant in 
the context of the high placebo response rates in MDD (47); supported by evidence of the 
N/OFQ system’s role in mood and observed antidepressant properties (132, 258).  Predicting 
placebo responders has valuable clinical application through augmenting the effort to 
differentiate drug-specific and placebo-specific effects and to better target neural circuitry 
associated with recovery for future treatments. Moreover, identifying placebo responders may 
enhance personalization of treatment, therefore improving treatment efficacy and concurrently, 
reducing treatment duration and costs (19, 161, 302). Altogether, these findings are suggestive of 
the potential role of the N/OFQ system’s role in depression placebo neurobiology; particularly 
since corresponding placebo mechanisms are believed to be engaged across disease states like 
pain and depression (77, 88).  
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Chapter Five 
Conclusions and Future Directions 
 
 Investigation into the neural basis of placebo responses in major depression has been 
largely unexplored. Yet, the mechanisms associated with this psychobiological phenomenon 
have critical potential in elucidating neural pathways implicated in resiliency to diseases like 
depression. These mechanisms contribute to the recovery from depression; therefore, their 
investigation may be an essential component in the overall research to improve treatment for the 
disease (67). One potential aspect of this study is to examine neurobiological predictors of 
placebo and antidepressant treatment responses in order to clarify the neurobiology associated 
with positive treatment outcomes and in order to better categorize patients on their susceptibility 
to respond to placebo or particular antidepressant treatments. Comprehensively, the 
antidepressant treatment response is composed of the ‘actual treatment effect’ + ‘placebo effect’ 
+ other non-specific effects, and because of this, clinical antidepressant trial outcomes are often 
inconclusive in separating drug and placebo effects (18). The placebo response is also present in 
clinical settings of antidepressant treatment. Therefore, predictors of interest are those which are 
specific to antidepressant treatment and those which are specific to placebo responses; their 
investigation serves to inform mechanisms specific to treatments and those specific to resiliency 
mechanisms against depression symptoms. This type of knowledge may further improve future 
treatment targets as well as stratify patients in clinical settings and clinical trials by their 
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likelihood of responding to placebo or particular treatments. Identifying likely placebo 
responders may signify that they may benefit from less intensive treatment in the form of smaller 
medication dosages or more comprehensive patient-clinician interaction. Elements of the placebo 
response may be capitalized upon to relieve patient suffering and improve overall treatment 
experiences and efficacy (242).  
Predictors of Antidepressant Treatment Effects 
 Here, we investigated predictors of placebo responses after one-week of placebo 
administration with expectations of antidepressant effects and predictors of antidepressant 
responses after ten week of an open-label antidepressant treatment. To do so, we employed a 
network-based resting-state functional connectivity perspective in order to capitalize on the 
inherent network-based organization of the human brain and the accessibility of the methodology 
– free from experimental task paradigm constraints. Specifically, we focused on the default-
mode (DMN), salience (SN), and executive (EN) networks within our investigation. We found 
that increased cohesion within the SN in the rostral anterior cingulate (rACC) was significantly 
predictive of greater reductions in depressive symptoms in response to one-week of placebo 
administration with expectations of antidepressant effects. Greater connectivity within the 
posterior insula (pINS) and dorsolateral prefrontal cortex (dlPFC) within the SN also contributed 
to this finding, however at lower statistical thresholds. The same pattern of enhanced SN 
connectivity within the pINS, dlPFC, and rACC also predicted greater reductions in depressive 
symptoms after ten weeks of open-label antidepressant treatment response; moreover, anterior 
insula (aINS) functional connectivity within the network demonstrated a relationship in an 
opposing direction.  
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Of interest, the positive predictive relationship between the rACC, dlPFC, and pINS and 
antidepressant responses were observed at a lower statistical threshold compared to their 
relationship with placebo responses. This may be indicative of these regions specifically 
predicting only the portion corresponding to the placebo response inherent within the total 
antidepressant response. Alternatively, SN connectivity may be predicting the interaction 
between active drug and placebo effects. However, further work within the context of a 
randomized clinical trial (RCT) employing parallel drug and placebo arms, and is of a substantial 
sample size, is essential to corroborate these findings and relevant hypotheses.  
 Remarkably, the two regions within the SN which were most prominent in the prediction 
of treatment responses were the rACC and INS. Existing literature describing MDD treatment 
neurobiology consistently identifies these two regions as treatment response predictors [reviewed 
(19, 96, 97)]. However, these findings have emerged by examination of isolated regional activity 
or in relation to an experimental task. In contrast, our work provides a comprehensive, intrinsic 
framework for the regions: functional connectivity within the SN during a resting state. This 
further implicates the network within the neurobiology of placebo responses as well as a 
component of the antidepressant treatment response, none of which has ever been demonstrated.  
Furthermore, we provide evidence of the rACC’s capability to significantly predict 
reductions in depressive symptoms in response to placebo administration with expectations of 
antidepressant effects. Pretreatment activity within the region is the main predictor of treatment 
response across imaging modalities and across antidepressant treatments (44, 136, 188, 303); 
moreover , it is a substantive indicator of sustained treatment response (27). Therefore, our 
finding that it predicts placebo responses may place prior work in new light: the region may be 
predicting non-specific effects of treatment or possibly, an interaction between treatment-specific 
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and placebo effects. In all, these findings begin to outline the primary neuronal component 
involved within a successful reduction in depression symptoms. The intricate role of the rACC in 
placebo analgesia neurobiology (57, 72, 113), further evinces that the rACC is a key element in 
resiliency mechanisms, or in homeostatic responses to stressors such as a depressive episode or 
experience of pain.  
Our findings regarding the insula are also of interest. Primarily, we found a dissociation 
between the anterior and posterior insular regions in their predictive capabilities. The aINS was 
observed to exclusively relate to antidepressant treatment response; specifically, decreased 
connectivity within the region was related to greater reductions in depression symptoms after ten 
weeks of open-label antidepressant treatment. This predictive pattern has been demonstrated in 
prior work, notably in a comprehensive meta-analysis of antidepressant treatment response 
predictors (97). However, alternative patterns of enhanced aINS metabolism have also been 
predictive of a better response to antidepressant medication (95); still, the region is theorized to 
be a strong marker of treatment selection. Particularly, lower levels of activity signify better 
response to cognitive therapy whereas higher levels are conducive to a patient requiring more 
intensive treatment (19). In contrast, the pINS was predictive of both placebo and antidepressant 
treatment responses. Interestingly, the one study to examine placebo neurobiology in MDD 
found aINS metabolism changes to associate specifically with antidepressant medication 
response, whereas increases in pINS glucose metabolism was associated with metabolism 
changes in both placebo and antidepressant responders (59). More posterior regions of the insula 
may be involved in shorter-term responses, mostly produced by placebo effects, while the aINS 
may be implicated in more long-term, sustained antidepressant treatment responses. While both 
areas are known to have cognitive functions, the pINS has more connections with areas in the 
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sensorimotor cortex and is involved with internal and external sensory perceptions while the 
aINS is better associated with autonomic, emotional, and higher cognitive processes (149). 
While both regions of the insula may be necessary for placebo and antidepressant responses, the 
aINS may have more executive and regulatory power to obtain longer-term, sustained 
antidepressant outcome. Correspondingly, treatment-induced modulation of the aINS is a 
pervasive marker of clinical outcomes (304).  
Neurobiology of Major Depression 
Following our investigation into treatment response predictors, a network-based resting-
state functional connectivity approach was employed to investigate neurobiological differences 
between depressed subjects and healthy functioning controls. Although group ICA produced null 
results, a further decomposition of the three investigated networks demonstrated diminished 
connectivity of the rACC within the SN in depressed patients compared to healthy subjects. 
Additionally, a major subset of the left EN also demonstrated decreased connectivity within the 
depressed group. Overall this speaks to greater cohesion within the rACC of the SN and the left 
EN in healthy functioning individuals compared to patients with depression. Furthermore, 
through a connectome approach, functional connectivity between major nodes of the DMN – 
rACC, posterior cingulate cortex (PCC), and the parahippocampus, as well as the subgenual 
anterior cingulate (sgACC) – was significantly reduced within depressed subjects.  
Altogether, these observations contribute to the understanding of neurobiological 
abnormalities attributed to MDD. Further examination is warranted to examine the psychological 
processes associated with these neural patterns; however, the emergence of increased rACC 
connectivity within the SN is of consequence. As described above, the region is intricately linked 
to antidepressant treatment responses and their success. Therefore, by demonstrating an 
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association between this rACC-SN pattern and healthy functioning individuals, these findings 
further progress the hypothesis that rACC is a central component to healthy cognitive-affective 
processing and contributes to the neural basis of MDD recovery. These observations also point to 
potential treatment targets for MDD. Notably, the major regions we observed to have greater 
functional connectivity in healthy controls have all been described as major nodes of the DMN, a 
network whose main responsibility is to monitor internal states of self (305). Aberrant 
downregulation and connectivity within the network has been described in MDD (23, 143). 
While the nature of its functional connectivity compared to controls is in debate (125), primarily, 
the network is believed to be dysregulated in MDD, mostly in relation to the engagement and 
disengagement of the SN and EN. The three networks are part of a triple network model: deficits 
in access, upregulation and deregulation of the three large-scale neural networks are 
hypothesized to serve as the major basis for affective and cognitive dysfunction in depression, as 
well as other psychopathologies (128).   
While extensive investigation into the nature of inter-network relationships is still needed 
to define their implication in MDD manifestation, our work points to potential nodes as targets 
for ultimate network regulation or normalization. Deep brain stimulation of the sgACC, also a 
hub of the DMN and identified as a major node within an emotional and mood regulatory 
network (14), is effective in treating patients with treatment-resistant depression (24).  
Alternatively, the rACC, PCC or parahippocampus may be potential treatment targets. Although 
possibly not anatomically ideal for surgical stimulation, their activity may be modulated with 
regional receptor-specific medications or stimulation through improved transcranial measures 
such as electroencephalography (EEG) or transcranial magnetic stimulation (TMS). 
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Alternatively, a neurofeedback task may be employed to engage and strengthen these regions 
within depressed patients.  
Finally, we investigated neuroimaging-genetic markers of placebo analgesia through the 
effects of genetic variations within the prepronociceptin gene (PNOC) – a gene with implications 
in MDD (132) – on placebo-induced µ-opioid neurotransmission and plasma cortisol levels. We 
also examined the relationship with levels of trait anxiety. The neurobiology of placebo analgesia 
has been extensively mapped so we sought to capitalize on this advancement to find potential 
clinical neuroimaging markers which may ultimately inform MDD placebo neurobiology. 
Moreover, our work also elucidated neural correlates of placebo neurobiology and not in the 
least, contributed to the development of the placebome (80). Research expanding the placebome 
serves to uncover genetic influences on placebo-associated pathways in order to identify 
candidate genetic markers for their eventual employment within clinical settings for a better 
assessment of likely placebo responders or for antidepressant clinical trials. Moreover, these 
markers may further uncover novel placebo-associated mechanisms; for instance, more details 
regarding aspects of neurotransmitter signaling or specific involvement of previously 
unexamined systems, such as the endocannabinoid system (54).  
Here, we identified a single nucleotide polymorphism with significant effect on placebo-
induced µ-opioid neurotransmission: individuals homozygous for the ‘A’ allele demonstrated 
greater µ-opioid  activation – within the rACC, pINS, and caudate which are established 
placebo-related regions (77) – and greater reductions in self-reported pain measures than their 
‘C’ carrier counterparts. Furthermore, the ‘A’ homozygotes’ increased perception of analgesic 
effects and associated µ-opioid-based neurobiological response was significantly related to 
decreases in plasma cortisol levels and, although at a trend, associated with lower levels of 
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anxiety. These findings contribute to a general understanding of placebo responses: well-
documented activation of the µ-opioid system, reductions in cortisol plasma levels, and lower 
levels of anxiety. The ‘C’ carriers confirmed these relationships as they demonstrated reduced µ-
opioid activation, increases in placebo-induced plasma cortisol levels, and higher levels of 
anxiety. This also contributes to defining the neural basis of nocebo responses, or worsening in 
symptoms following placebo administration with expectations of therapeutic effects. 
These results inform potential predictors of placebo responses in the form of genetic 
markers and anxiety traits. Their relation to the placebo response is corroborated by neural 
correlates in the form of µ-opioid activation and plasma cortisol decreases. These findings in 
placebo analgesia can be extended to investigate neurobiological mechanisms and correlates of 
placebo responses in MDD. Overlap in mechanisms may point to general resiliency mechanisms 
to homeostatic stressors such as pain or a depressive episode. Moreover, these and disease-
specific placebo mechanisms may point to potential targets for future treatments. These findings 
also point to the potential of PNOC as a genetic predictor of placebo responses in MDD, 
especially since prepronociceptin and members within its opioid family are associated with 
depression (255). As in this chapter, a similar design with administration of a placebo with 
described antidepressant properties may uncover the acute neural mechanisms responsible for 
reductions in depressive symptoms, or depression recovery as well as investigate potential 
predictors of placebo response. Initial work in this regard has been described (88), yet further 
investigation is merited.  
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Rostral Anterior Cingulate 
 Emergent from our findings is the significance of the rACC within the neurobiology of 
placebo responses as they relate to MDD, healthy functioning, and placebo-induced opioid 
neurotransmission under genetic influences. Firstly, we found that functional connectivity of the 
region within the SN to be significantly predictive of reductions in depressive symptoms in 
response to one week of placebo administration with expectations of antidepressant effects. The 
region was also predictive of the response to ten weeks of antidepressant treatment, although at a 
lower statistical threshold. This weaker association may stem from its predictive nature to be 
specific to placebo responses inherent within the overall antidepressant treatment response or a 
drug-placebo interaction (however, it may also be due to the long-term nature of the 
antidepressant response measure or the reduced sample size in our study). Moreover, rACC 
functional connectivity within the SN was significantly reduced within a group of depressed 
patients compared to healthy subjects. This overlap in more cohesive rACC functional 
connectivity within the SN predicting reductions in depressive symptoms as well as being 
characteristic of a group of healthy functioning individuals is indicative of the potential 
significance the region has in a successful antidepressant response. More generally, the region’s 
role within the SN may underlie the neural basis of the employment of adaptive neural 
processing within depressed patients which better matches the healthier affective-cognitive 
functioning of healthy individuals. Similar findings have been observed when examining 
pretreatment glucose metabolism in depressed patients: in comparison to healthy controls, rACC 
hyper-metabolism differentiated eventual antidepressant medication responders from the non-
responders who demonstrated hypo-metabolism in the region (44). Moreover, normalization of 
heightened rACC activity upon a successful response to treatment has been observed within 
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patients with MDD undergoing sleep deprivation (190). We demonstrated a similar pattern of 
equilibration of heightened rACC connectivity within the SN to associate with greater reductions 
in depressive symptoms in response to placebo treatment.  
Anatomically, the rACC lies within a cross-section between dorsal higher-order cognitive 
regions involved in executive, goal-directed cognition and ventral lower-order limbic regions 
involved in more primitive emotional responses such as anxiety and fear (27, 46); therefore, the 
primary responsibility of the rACC is to modulate and regulate top-down and bottom-up 
communication (306). Furthermore, the region is believed to inadequately modulate these 
communication pathways, which are already abnormal, in depression (44). Moreover, the region 
is also well-suited to foster antidepressant functioning as it demonstrates a key role within self-
referential processing of emotional stimuli (45), evaluation of emotional significance of events 
(307) and resolving emotional conflicts (115), as well as cognitive-based processes including 
decision-making related to reward and error evaluation (216). In all, this enables the ultimate 
expression of affect and goal-directed behavior through integration and regulation of salient 
affective and cognitive information (96). Taken altogether, it’s possible that the comprehensive 
functioning of the rACC contributes to antidepressant responses through strengthened regulation 
of a classic characteristic of MDD: irregular and heightened reactivity to negative stimuli within 
the internal and external environments. It may also serve to better recruit the executive, inhibitive 
functioning of upper-order cognitive regions. Nevertheless, more comprehensive investigation is 
warranted to determine the absolute psychological cognitive-affective processing occurring 
within the region prior to antidepressant treatment and during the engagement of a successful 
antidepressant response.  
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Although not reported, we also found increased functional connectivity within the rACC 
in the DMN to associate with better response to ten weeks of antidepressant treatment, albeit at a 
lower statistical threshold. This is in line with hypothesis that the role of the rACC within this 
network, which is associated with introspective processes forming the internal world of the self 
(305), may underlie a major portion of the neurobiology within a maintained anti-depressive 
state (96). On the other hand, the region’s role within the SN may attribute to more immediate 
antidepressant responses, such as the placebo response. This is in line with SN functioning: the 
network is involved in selecting and orienting to relevant, salient stimuli and incorporating this 
information with interoceptive states to guide behavior (147). Therefore, placebo responses may 
materialize from the incorporation of expectations and contextual cues from the therapeutic 
environment via the self-referential and saliency-dependent processes of the rACC within the 
SN. While connectivity between the rACC and the DMN may engage more intimately with 
maintained antidepressant responses through formulating and sustaining an updated internal 
environment free from major depressive episodes. Possibly, some of the effects of the initial SN-
driven antidepressant response may be translated to or acquired by the DMN functioning for 
continuation of the antidepressant response. However, more comprehensive research utilizing 
resting-state functional connectivity within a long-term RCT with parallel placebo and 
antidepressant arms will better illustrate the viability of this hypothesis. 
Lastly, our findings highlight the central role of the rACC within neural pathways 
implicated in resiliency from homeostatic stressors such as a depressive episode or pain. Within 
these chapters, we found that functional connectivity in the region within the SN is associated 
with predicting reductions in depressive symptoms and in juxtaposition, is more cohesive in 
healthy individuals compared to depressed patients. Additionally, we found a gene effect on 
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placebo-induced opioid neurotransmission within the region that is related to placebo analgesic 
effects and related-stress responses. Moreover, the associated gene, PNOC, has antidepressant 
therapeutic potential (258). Altogether, this illustrates the ability of the region to foster general 
healthy functioning and resiliency across disorders. In addition, these findings place the SN in 
the context of placebo neurobiology, which may be the inherent framework for rACC 
mechanisms observed in placebo analgesia as well. Broadly, these findings advocate for future 
research into the particular psychological mechanisms involving the rACC that contributes to 
adaptive cognition and emotion regulation as well as further work into the region’s 
communication within wide-spread, intrinsic networks such as the SN and DMN.  
Future directions for treatment of Major Depression 
 Our results serve to inform the neurobiology of recovery from MDD. Potential 
therapeutic targets for MDD may result from these findings: the development and 
implementation of therapies which are based on enhancing the recruitment and engagement of 
rACC functioning or treatments which specifically target the region in vivo via its 
cytoarchitectural characteristics. Possibly, this could be implemented through the development of 
antidepressant pharmaceutical drugs which exert their effect through specific receptors (or sub-
receptors) highly localized within the rACC. For instance, upregulating a class of serotonin 5-HT 
receptors within the region is hypothesized to strengthen inhibition of excessive limbic activity 
in regions like the amygdala (308).  
 Our findings also inform clinical neuroimaging predictors of antidepressant treatment 
response which may be implemented within the context of a clinical setting. By examining 
patients’ SN resting-state functional connectivity or through genetic screening, clinicians may 
recognize patients with greater susceptibility to placebo effects. Consequently, clinicians may 
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prescribe these patients lower dosages of currently available antidepressant medications or 
recommend a more cognitive-based approach to treatment. However, the hypothesis that greater 
likelihood of placebo responsiveness translates into better response to psychotherapy will have to 
be evaluated. Still, enhanced interaction with the clinician and time-spent within a therapeutic 
environment may influence antidepressant responses in these patients. Recent data show that 
three quarters of placebo responders remain well even after a period of twelve weeks into the 
continuation of placebo treatment (61), which suggests that placebo effects are not transitory. 
Moreover, as placebo rates vary between antidepressant clinical trials (18), it is believed that the 
trials with larger placebo responses are more therapeutic and thus, may provide a framework in 
examining beneficial environmental influences on placebo responses. Insights from these studies 
may be implemented in patient-clinician protocols within actual clinical settings. For instance, 
increases in required doctor visits has shown to improve depressive symptom reduction (309). 
Additionally, interaction with clinicians demonstrating an optimistic and warm demeanor as 
compared to those who are more pessimistic and less friendly significantly improved patients’ 
clinical responses (310). Moreover, physical attributes of the treatment like pill color, dosing 
regimen and even sophistication of the treatment procedure can influence clinical placebo 
outcomes (311). 
 Within antidepressant clinical trials, our findings may augment the stratification of 
patients through the potential clinical neuroimaging predictor of enhanced rACC connectivity 
within the SN or genetic markers such as PNOC polymorphisms. This is especially relevant in 
the former marker as we found it capable of predicting placebo antidepressant responses with 
significant accuracy at an individual level. Those individuals demonstrating a greater likelihood 
of placebo response may be stratified to better investigate isolated placebo effects or 
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comprehensive interaction between active treatment effects and placebo. Moreover, those with 
little likelihood of placebo response may uncover more drug-specific antidepressant effects; 
however, those patients may have alternative neurobiological processing that is conducive to a 
nocebo effect, or worsening in symptoms, which will also have an interaction with active 
treatment effects. Regardless, expanding clinical trials to investigate placebo, nocebo and drug 
effects as well as the inter-relationships between these processes will provide a more 
comprehensive evaluation of antidepressant effects for a widespread and variable sample of 
depressed patients. This will better match the highly inter-individual variations within the total 
population of depressed patients who are seeking treatment and therefore, contribute to the 
development of more effective antidepressant drugs.  
Concluding Remarks 
The neural basis of the placebo response as it relates to MDD is an important avenue in 
progressing our understanding of the neurobiology behind the amelioration of depressive 
symptoms. Identifying the neural markers and players within these antidepressant responses and 
non-responses may enhance our ability to predict treatment responses and consequently, to better 
tailor antidepressant treatment protocols for each patient. Furthermore, uncovering these 
placebo-associated resiliency mechanisms against depression may also serve to expand the scope 
of potential targets in the development of efficacious antidepressant treatments. Potential clinical 
neuroimaging markers, such as rACC resting-state functional connectivity within the SN or 
genetic markers within the placebome, may substantially improve clinical practice by 
recognizing patients with high susceptibility to placebo effects to modulate their treatments. 
Subsequently, this may be implemented within clinical antidepressant drug trials to better 
differentiate between specific active pharmacological effects and placebo effects. Moreover, 
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these predictive markers cannot be confounded by factors such as regression to the mean or the 
natural course of illness which often challenge antidepressant efficacy measurements. Finally, 
within a more comprehensive picture, further defining the neural, molecular and cognitive bases 
of placebo neurobiology and the corresponding predictors of placebo responses informs our 
understanding of the neurobiological networks and related emotional-cognitive processes which 
combat stress and illness and enable a return to healthy, homeostatic states. Findings of this 
nature ultimately have comprehensive applicability within general and depression-related clinical 
care. 
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